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Abstract 
Malaria is an infectious disease caused by protozoan parasites of the genus Plasmodium. It 
remains a major cause of morbidity and deaths in many developing countries – an estimated 445,000 
people died from malaria in 2016. The symptoms of malaria occur during the blood-stage of infection, 
and can vary from asymptomatic infection to life-threatening syndromes such as cerebral malaria. 
The disease severity often correlates with the number of blood-stage parasites in the body. It is likely 
that both host and parasite factors are involved in determining parasite growth kinetics in vivo. 
However, our understanding of these factors is limited. Given that an effective malaria vaccine 
currently remains elusive, and that resistance has emerged against the currently available anti-malarial 
drugs, it is important to identify new approaches for controlling the number of parasites in blood in 
vivo. 
I have used experimental mouse models of blood-stage Plasmodium infection to directly measure 
parasite maturation, clearance and replication rates in vivo. I observed that parasite control can be 
achieved in a number of ways including: (i) the use of anti-malarial drugs that inhibit or arrest parasite 
development within a red blood cell, (ii) the use of drugs that prevent parasites from progressing from 
one generation of red blood cells to another, (iii) by host phagocytes actively removing parasitised 
red blood cells, and (iv) by host-mediated impairment of parasite maturation within red blood cells.  
Next, I identified the mechanisms of antibody-mediated parasite control using P. yoelii 
17XNL and P. chabuadi AS infection models. The experiments that I conducted demonstrated that 
the Plasmodium-specific antibodies in these systems provide robust protection against homologous 
re-challenge not by accelerating clearance of infected pRBC but by preventing asexually replicated 
parasites transitioning from one infected red blood cell to the others.  This correlated with an inability 
of Plasmodium-specific IgG to bind to the surface of pRBC, despite showing its clear specificity for 
the parasite proteins.  I also observed that the efficacy of antibody-mediated immunity depended on 
phagocytes, but not on the complement factors C3/C5.   
Finally, hundreds of Plasmodium-exported proteins, known collectively as the “exportome”, 
remodel host RBC, and yet the precise functions of many of these as well their ability to promote host 
interactions remain unclear. Using a high-throughput, barcode-based forward genetic screen in 
immunocompetent and immune-deficient mice, I screened 117 exportome-associated genes to 
understand their in vivo function and possible host-interaction. I demonstrated that 32 of these genes 
were essential for blood-stage growth, including 8 with no previous functional annotation. Further 
analysis revealed that 10 genes were required for growth in the presence of an intact immune system, 
which were not required for growth in immune-deficient mice. This study provides proof-of-principle 
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that although parasite genes are not essential for blood-stage growth per se but they are required in 
combating the host immune responses. 
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Chapter One 
Introduction 
1.1 Malaria 
Malaria is a disease caused by infection with the protozoan parasites belonging to the genus 
Plasmodium. The word malaria originated from Italian words “mal aria” meaning “bad air” as it was 
believed that the disease was caused by an unknown substance in the air from swamps [1]. Today, 
malaria remains one of the four major life-threatening infectious diseases globally. According to the 
latest estimates from the World Health Organization (WHO), 216 million cases of malaria occurred 
in 91 countries with 445,000 deaths in 2016 (WHO report 2017). Nearly 80 % of the cases and 90 % 
of the deaths are reported from sub-Saharan Africa, and children under the age of 5 years and pregnant 
women are the most severely affected [2]. Malaria is a vector-borne disease, transmitted by female 
Anopheles mosquitoes, and different species of the parasite infect a wide range of hosts including 
humans, monkeys, rodents, birds and reptiles. Human malaria is caused mainly by four different 
species of Plasmodium: Plasmodium falciparum (Pf), Plasmodium vivax (Pv), Plasmodium ovale 
(Po) and Plasmodium malariae (Pm). A fifth species Plasmodium knowlesi that infects primates, has 
also caused human malaria but the exact mode of transmission remains unclear [3, 4]. 
Plasmodium falciparum causes the life-threatening disease, cerebral malaria, which prevails 
in Africa and accounts for the majority of global morbidity and deaths. P. vivax generally produces 
milder disease and has recently been reported among the population living in sub-tropical Africa in 
addition to other areas at risk, and may persist in the liver as hypnozoites forms for several months to 
years causing relapses; while the incidence of the other three species is currently much lower. 
The clinical symptoms of malaria include fever with chills, sweating, fatigue, nausea, and 
anemia. However, the severe form of malaria due to P. falciparum can lead to life-threatening 
conditions including respiratory distress, metabolic acidosis, seizures and unconsciousness/ coma, 
and rapid death. The complex life cycle of Plasmodium spp. alternating between female Anopheles 
mosquitoes and vertebrate hosts has made understanding of the host-parasite interactions and 
infection control difficult. Plasmodium parasites enter the host through the bite of an infected 
Anopheles mosquito injecting sporozoites present in their saliva into the dermis, followed by infection 
of the hepatocytes and undergoing a pre-erythrocytic liver stage that lasts for 1-2 weeks before entry 
of the parasite into the blood stage [5]. In the hepatocytes the sprozoite undergo asexual development 
releasing merozoites in the hepatic circulation to invade erythrocytes in a rapid, dynamic and multi-
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step process - pre-invasion, active invasion and echinocytosis. Pre-invasion involves robust 
interaction between merozoite and erythrocyte through actomyosin motor causing deformation of the 
erythrocytes. A short time later, merozoite moves into the erythrocyte through a pinch-point (the 
tight-junction) and undergoes asexual development in its intra-erythrocytic life-cycle [6]. This life-
cycle includes progression through the ring, trophozoite, and finally the mature schizonts stages 
producing tens of daughter merozoites for re-invading new RBCs - a cyclical process that is 
responsible for the onset of clinical symptoms. As parasites reside and develop within RBCs, they 
bring about physiological and biochemical changes within host cells [7]. Moreover, interactions by 
way of parasite-encoded molecules may affect the mobility and trafficking of RBCs within the host, 
possibly increasing the infection severity. A sub-population of intra-erythrocytic parasites gives rise 
to the sexual-stage parasites (gametocytes), which migrate to peripheral blood vessels in the skin.  
These are then taken up by feeding mosquitoes, which completes the cycle through the generation of 
sporozoites by sexual reproduction in the midgut of the mosquito and their moving into the salivary 
gland - ready to infect new hosts via a blood meal [8, 9]. 
 
Figure 1.1 Life cycle of Plasmodium spp. The parasites (sporozoites) are transmitted to a human 
host via the bite of an infected female Anopheles mosquito. Sporozoites migrate through the skin and 
are taken up by the hepatocytes. Here, they undergo asexual reproduction to produce merozoites. 
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Merozoites enter the blood stream and quickly infects RBCs. Within the RBCs, merozoites hijack host 
machinery and undergo the ring, trophozoite, and mature schizonts stages followed by rupture of the 
infected RBCs (schizogony) and release of more merozoites. The merozoites thus released infect new 
RBCs to either continue multiplying or, alternatively, develop into the sexual-stage of the parasite 
(gametocytes). The gametocytes migrate to the dermis where they may be taken up by mosquitoes, 
and undergo sexual reproduction to continue its life cycle[10]. 
 
1.2 The rodent model of malaria 
  In the field of malaria research, the rodent model is very important as the laboratory 
maintenance of the complete P. falciparum life-cycles remains very difficult. Rodents are the best 
non-primate models. Since their isolation from the wild between 1948 and 1974 in Central West 
Africa, rodent malaria parasites, Plasmodium berghei (used in this project), P. chabaudi, P. vinckei 
and P. yoelii, have enabled us studying various aspects of host-parasite-vector interactions, due to our 
easy access to stages of the parasite in mosquitoes and in host livers in order to evaluate potential 
interventions in malaria control [11]. Although none of the rodent Plasmodium species is the perfect 
model for P. falciparum, different species can be used to study different aspects of the infection. For 
instance, P. chabaudi is a model that best to understand the interplay between the parasite and the 
host immune response, while P. berghei is a better model for studying the biology of 
transmission[11]. 
 
In addition to laboratory study of the parasite life cycle, rodent malaria parasites are more amenable 
to genetic modifications than P. falciparum [12]. In fact, it can take as little as two weeks to obtain a 
clonal population of P. berghei transgenic parasites, which will take at least two months for the human 
parasites. Moreover, the availability of fluorescent rodent parasite lines and transgenic mice permits 
exploration of specific host parasite interactions that are not yet available for studies of human malaria 
parasites [13]. 
 
  
1.3 Progress in infection control measures 
Between the years 2000 and 2013, the malaria prevalence and mortality have substantively 
declined by 48% and 47% respectively  [14]. A combination of improved vector control and drug 
treatment, especially the use of insecticide-treated bed-nets (particularly protecting young children), 
indoor residue spraying, and development and use of newer and more effective anti-malarial drugs 
have contributed to this decline. Unfortunately, the emergence and spread of drug-resistant parasites 
has contributed to the re-emergence of malaria, and also has stagnated malaria control [2].  
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Despite decades of intense research, there is currently no effective vaccine against malaria. 
The leading malaria vaccine candidates include RTS,S/AS01, a pre-erythrocytic vaccine based on the 
circumsporozoite protein (CSP) combined with hepatitis B surface antigen; AS01, a combination of 
mono-phosphoryl lipid A (MPL, a toll-like receptor 4 agonist); and QS21 (a derivative from Quill A) 
and lipids [15, 16]. The results from phase III clinical trial of RTS,S on 15,460 children in seven 
countries in the sub-Saharan Africa suggested its relatively low efficacy (26-50%) in reducing the 
malaria episodes in children with and insignificant effect on deaths [17].  
A numbers of combined vaccines are in the process of development, which are intended to 
target a range of Plasmodium antigens that are expressed at different stages of life cycle, such as, 
GRURP-Pfs48/45 - a multistage, chimera vaccine; PfSPZ - a whole attenuated, purified, 
cyropresevered vaccine; and transmission-blocking vaccine [18] [19, 20] [21]. Despite serious efforts, 
the progress has been slow due to major gaps in understanding host-parasite interactions and 
protective immunological mechanisms. It is thus important to understand the biology of the parasite 
for identifying potential vaccine candidates, as well as understanding how to generate protective 
immunity via next-generation vaccines.  
Antimalarial drugs are effective in the treatment and control of malaria, especially the 
Artemisinin Combination Therapy (ACT). Artesunate (an artemisinin derivative) is the WHO-
recommended treatment for patients with uncomplicated malaria due to its greater ability to reduce 
parasite numbers than the other antimalarials [22-24]. Artesunate acts faster and also acts over a wider 
range of parasite developmental stages than the other anti-malarials [25]. However, the emergence of 
Artemisinin resistance highlights the importance of understanding the mechanisms of drug resistance.  
Many studies have reported that the use of the short course monotherapy with Artesunate has been 
responsible for emergence of resistance in Southeast Asia [26, 27]. Artesunate, short-acting drug has 
been combined with a longer-acting antimalarial drug, to develop ACT (Artemisinin-based 
Combination Therapy) to prevent/delay the emergence of resistance. Artesunate-mefloquine therapy 
is one such combination; compared to artesunate mefloquine produces a slower decline in the total 
number of parasites but it has a longer half-life and additionally it also destroys the asexual blood-
form of a malaria parasite. Slower parasite clearance under artesunate treatment has recently been 
observed in western Cambodia and adjacent border of western Thailand [28, 29], which has been 
interpreted as evidence for the emergence of Artemisinin-resistant parasites [29]. 
In endemic populations, the naturally-acquired immunity to malaria might require 10-15 years 
of exposure to the parasite to develop [30]. Studies have shown that in countries with high 
transmission rates, such as Kenya and Gambia, the incidence of cerebral malaria and severe malaria 
were the lowest [31] [32] [33, 34], while severe malaria continues to occur among older children and 
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adults in areas with low transmission [35, 36]. These observations suggest that there is a strong 
relationship between parasite exposure and immunity to malaria, and support the argument that 
implementing control measure to prevent the transmission of infection could contribute to the poorer 
outcomes for some individuals infected with Plasmodium [37]. Therefore, a better understanding of 
host-parasite interactions may aid the development of new malaria control measures.  
1.4 Host-parasite interaction  
The life cycle of malaria parasite is complex since it occurs in different tissue sites in two 
different hosts – the vertebrate human host and the female Anopheles mosquito. The outcome of 
infections depend on the interactions between the host and the infecting species of Plasmodium. 
Parasites reside and develop within host RBCs, where they bring about changes in the physiological 
and biochemical processes within these host cells [7]. 
During the blood-stage malaria, the initial attachment of parasites to host erythrocytes occur 
through the interactions between erythrocyte receptors and parasite ligands of two protein families, 
the Erythrocyte Binding Ligands (EBL) family of proteins and P. falciparum reticulocyte binding 
protein homolog (PfRh or PfRBL) proteins that are present on merozoite surface [38, 39].  
Merozoites can invade mature RBCs using two independent pathways - a sialic acid (SA)-
dependent [40] and a SA independent one. Parasite molecules involved in the sialic acid-dependent 
pathway are the Erythrocyte Binding Ligands (EBL) family of proteins. During the invasion process, 
micronemes-apical organelles of merozoites contain the EBL proteins EBA-175, EBL-1, EBA-140 
that binds to major sialyated proteins on the surface of RBC such as glycophorins A, B and C 
respectively [41-43] - the major sialyated proteins on the RBC surface. Among Reticulocyte-binding 
protein Homologue (RH), PfRH1 is the only member that binds SA residues, and PfRH2, PfRH4, 
PfRH5, and MSPs are components of the SA-independent pathway in which human erythrocyte band 
3 function as a receptor [44, 45]. It was thought that targeting of proteins involved in the invasion 
process is less tractable because of multiple redundant pathways and extensive sequence variations 
in the parasite proteins. However, it has recently been suggested that PfRH5 is essential for invasion 
process since it cannot be deleted in any strain of P. falciparum [46] and it is a ligand for the host 
receptor Basigin [47, 48]. The blocking of PfRH5-basigin interaction by soluble basigin, basigin 
knockout or anti-basigin antibodies were shown to protect against malaria by blocking merozoites 
invasion of multiple strains of P. falciparum [49], and thus has been proposed as a novel drug target 
in malaria [50].  
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On the other hand, it has also been observed that delivering of PfRH5-based vaccines to Aotus 
monkeys provided protection against challenge with heterologous-strain of blood-stage P. falciparum 
in vivo, and the protection depended on the concentration of anti-PfRH5 antibody and parasite-
neutralizing activity [51].  Moreover, anti-PfRH5 antibody, derived from natural human infections, 
has erythrocyte invasion inhibitory functions in vitro [52] as well the ability to reduce risk of malaria 
in children by increasing the concentrations of IgG3 subclass of antibodies against PfRH5 [53]. Thus, 
PfRH5 is considered an important candidate in anti-malarial vaccine research development. 
Additionally, apical membrane antigen (AMA1) and rhoptry neck protein (RON) have been 
shown essential for RBC invasion by triggering junction formation [54], with AMA1 perceived as a 
target vaccine candidate for inducing naturally-acquired protection against malaria [55, 56], since it 
is immunogenic and is safe for use in human [57]. However, the polymorphic nature and strain-
specific protection limits its use [58]. 
Erythrocyte receptors, on the other hand, play an important role in the merozite invasion 
process. CD55 is a 70 kDa glycoprotein attached to the erythrocyte membrane by a 
glycosylphosphatidylinositol (GPI) [59]; CD55 knock-down results in significant reduction in 
parasite invasion while CD55-null cells were found resistant to invasion [59].  
Following invasion, parasites within the human erythrocytes undergo an intra-erythrocytic 
cycle that includes its progression through the ring, trophozoite and mature schizont stages, during 
which the parasites extensively remodel the infected red blood cells (pRBCs) by exporting several 
hundred proteins into the host cytoplasm, some of which can serve as ligands for adhesion to 
endothelial receptors [60]. Remodelling of iRBCs requires the development of a tubulovesicular 
network to sort and distribute proteins to target locations beyond its own plasma membrane (PM) and 
the parasitoporous vacuole membrane (PVM). Key exomembrane-bound structures of various sizes 
are formed during the construction of this network, including Maurer’s clefts (MCs) [61], electron 
dense vesicles (~80 nm diameter) [62, 63], and J-dots [64]. Early in the intra-erythrocytic cycle (i.e. 
within 5 hours of invasion), the parasite generates MCs via budding from the PVM, and begins 
exporting proteins into the erythrocyte cytoplasm. Subsequently, parasites develop into trophozoites 
(5-10 hours post-invasion) and MCs migrate towards and become tethered to the erythrocytic 
membrane. These structural changes to the host RBC increase its rigidity [65]. For example, during 
P. falciparum infection, RBC surface “knob” formation is accomplished by the knob associated 
histidine-rich protein (KAHRP) and adherence of the iRBC to the vascular endothelium [66] via 
binding of P. falciparum erythrocyte membrane protein (PfEMP1) to a host receptor. The PfEMP1 
protein family is antigenically highly diverse since they are encoded by 60 var (variable) genes per 
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haploid genome [67-70]. This high sequence diversity in PfEMP1 proteins facilitates evasion of the 
host immune response, exacerbating the pathology and disease severity [71].  
Duffy binding-like domain (DBL) α, the N-terminal region of PfEMP1 play a key role in 
binding to uninfected erythrocytes via glycosaminoglycan heparin sulphate [72] in a process called 
rosetting that obstructs flow of blood in micro-capillaries [73]. It has recently been shown that anti-
coagulants, heparin and sevuparin can block this resetting and has thus been proposed as possible 
adjunct therapies for severe malaria [74]. Host platelets may also play a protective role in the early 
stages of blood-stage infection by binding to the infected erythrocytes and killing the parasites within 
[75]. 
PfSEA, a parasite protein involved in RBC egress, is considered a potential immune target 
since anti-PfSEA antibodies are able to slow down parasite replication by arresting schizont rupture. 
However, the mechanism by which anti-PfSEA-1 antibodies access intracellular schizonts is not clear 
[76, 77]. It has recently been observed that the parasiteproteins plasmepsins IX and X are essential 
for invasion and egress controlling maturation of the enzymes subtilisin-like serine protease SUB1 in 
exoneme secretory vesicles that are required to disrupt the host cell membranes. Therefore, 
plasmepsins are selected as a potential drug target, by way of inhibiting its function using an enzyme 
inhibitor such as aspartic protease- a hydroxyl-ethyl-amine-based scaffold compound [78, 79].  
 
1.5 Host immune response during blood-stage malaria  
Humoral immune responses primarily confers immunity to blood-stage malaria; ; cellular and 
innate immune responses also play important role in controlling parasite growth but they may also 
contribute to malaria pathology [80]. Humoral or antibody and T cells responses are important of 
merozoites and intra-erythrocytic parasites respectively. Antibodies may opsonise merozoites to 
uptake or inhibit their invasion of RBCs. A number of in vivo mechanisms proposed to be involved 
in the control of pRBCs by antibody include cellular killing via phagocytosis, blocking of rosetting 
of RBCs, and neutralization of parasite toxins to prevent excessive inflammation [81]. Studies in 
humans infected with Plasmodium falciparum and in experimental mouse models suggest that both 
CD4+ T helper 1 (Th1) cells and interferon-γ (IFN- γ) are critically required to control the primary 
peak of parasitemia [82, 83]. A balance between pro-inflammatory and anti-inflammatory responses 
is also important in limiting the development of immune-mediated pathologies such as cerebral 
malaria and anemia [84]. Monocytes, macrophages, ploymorphonuclear granulocytes (PMNs) and 
dendritic cells (DCs) play important role in parasite clearance [85-88]. Macrophages in spleen and 
liver mainly involved in the phagocytic removal of malaria parasites [89, 90]. Phagocytic response 
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occurs through interaction between pathogen-associated molecular patterns (PAMPs) of parasitic 
origin and pattern recognition receptors (PRRs) on the host cell surface [91, 92]. These interactions 
activate a cascade of distinct transcriptional programmes and multiple downstream signalling 
pathways that support parasite clearance [93-95]. Additionally, complement factors opsonize and 
enhance phagocytic removal of parasites [85, 96]. The immune response during malaria is very 
complex and dynamic, which influences the severity of infection [97]. The level of expression of 
several cytokines such as IL10, TGF-ß, IL-17, IFN-γ, TNF-α, IL-6, IP-10, TNF-R2, TLR2, IL-8, IL-
15, MCP-1, EOTAXIN, and IL-5 have been found to alter with the disease conditions. Therefore, 
targeting the pathways involved in these processes could lead to novel therapeutic interventions. 
Interleukin IL-18 plays a protective role in malaria by mediating the IFN-γ production [98], and 
natural killer (NK) cells are involved in the early control through production of IFN-γ [99]. Tumour 
Necrosis Factor-alpha (TNF-α) has been observed to reduce intracellular parasitemia by reducing 
erythrocyte invasion process [100].  
 
1.6 Mechanisms of antibody-mediated parasite control in malaria 
Antibodies are important component of acquired-immunity to malaria, which has been 
demonstrated in the fundamental studies in which passive transfer of immune serum, firstly in rhesus 
monkeys [101] and later in malaria-infected children resulted in the reduction of parasite load along 
with improvement in the clinical status [102-104]. These findings demonstrated that parasite-specific 
antibodies are able to effectively control the number of parasites in human infections as well in in 
vivo animal models.  
In endemic populations, development of naturally-acquired immunity to malaria takes as long 
as 10-15 years of exposure to the parasites [30].  Efforts had been made to identify potential antigenic 
targets of protective antibodies [105, 106]. Mechanisms by which they control parasite numbers in 
vivo have also been reviewed [105, 107-109]. Protection against malaria is thought to depend on the 
functionality of antibody produced against either parasite proteins exported on the surface of pRBC 
or to those expressed on the surface of the merozoites [105]. The mechanism by which antibodies 
protect against malaria remains unclear, although this information is a key to development of effective 
anti-malarial vaccines.  
A number of possible antibody-mediated mechanisms have been proposed and disclosed in 
elegant in vitro assays. These include Growth Inhibition Assays (GIAs) [110, 111] to assess if 
antibodies can reduce parasite growth in the RBC over a few replication cycles; opsonic phagocytosis 
assays and antibody-dependent cellular inhibition (ADCI) assays [112-114] to assess whether 
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antibodies facilitate uptake and/or inhibition by phagocytes; and complement-fixing and killing 
assays [115, 116] to assess how well the antibodies facilitate C1q deposition and complement-
dependent direct killing. There is a lack of clear understanding of the correlation between functional 
efficacy in GIAs and immunity to malaria [117-120]; however, in recent years development of 
capacities to mediate opsonic phagocytosis or C1q-fixation in vitro, mostly of merozoites, have 
demonstrated its correlation with protection against P. falciparum malaria symptoms and high density 
parasitemia [114-116]. More recently, it has been suggested that antibodies against the pRBC surface 
protein, PfEMP1, which drive opsonic phagocytosis in vitro, afforded partial protection against 
malaria and that these antibodies develop slightly earlier than the merozoite-targeting antibodies 
[121]. The epidemiological data in humans supports the notion that multiple mechanisms act together 
against merozoites and pRBC in the antibody-mediated pRBC control during the blood-stage 
infection. However, few, if any of these mechanisms, have been convincingly observed in vivo.  
 
1.7 Measuring parasite clearance and growth in vivo 
During blood-stage Plasmodium infection, the total number of parasites may increase until 
the host-mediated control or drug intervention slows down or halts parasite growth (Figure1.2) [122-
125]. It is also believed that parasite clearance is accelerated by host clearance mechanisms, e.g. 
splenic pitting [122, 126, 127], or phagocytosis [82, 128]. Measuring parasite clearance in vivo is 
difficult, especially during the period of parasite replication. During active infection the total parasite 
load in the body depends on two competing processes: 1) host control of parasite numbers, and 2) 
parasites maintaining their numbers. The rate of parasite population growth likely depends on the 
replication efficiency of the parasites that is influenced by the number of merozoites produced from 
each parasite, and their survival capacity and ability to invade newer RBCs minus the rate of parasite 
clearance or control by the host. Therefore, to identify treatments and interventions that act by 
impairing parasite proliferation and those that act by enhancing host removal of parasites, we need to 
quantify parasite replication and control in vivo.  
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Figure 1.2 A hypothetical parasitaemia curve during blood-stage malaria showing that the resulting 
parasitaemia is the net effect of the parasite replication rate minus drug or host-mediated parasite 
clearance over the course of infection.  
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1.8 Thesis hypothesis, and aims and overall objective  
Hypotheses:  
1. Increased host clearance or reduced parasite replication is responsible for host- or drug-
mediated parasite control in vivo. 
 
2. In mouse model, Plasmodium-specific antibodies control infection by inhibiting the invasion 
of RBC, via binding to merozoites. 
 
3. During blood-stage infection, parasites export some proteins to subvert host immune 
control.  
 
Aims: 
1. To explore the mechanisms of parasite control during blood-stage malaria using an in vivo 
mouse model, Plasmodium berghei ANKA; 
 
2. To determine mechanisms by which antibodies control parasite numbers during non-lethal 
blood-stage malaria 
 
3. To identify novel Plasmodium exported proteins that are involved in host interaction.  
Overall Objective: 
The overall objective of my doctoral study (Ph.D.) was exploration of host mechanisms of parasite 
control during blood-stage malaria in vivo in rodent malaria model.  
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Chapter Two 
Study material and methods 
2.1 Materials  
2.2.1 Mice and their ethical use in the experiements 
 
Mice/rats Description 
C57BL/6 Immune competent,  6-12 weeks old female mice 
Balb/c Immune competent , 6-12 weeks old female mice 
rag1-/- Immune deficient (T and B cell deficient), 6-12 weeks old 
female C57BL/ 6 background mice  
SCID Immune deficient, 6-12 weeks old female Balb/c background 
mice 
Wistar rats Used to propagate parasites to be transfected in the screening of 
117 KO vectors. Outbred, 200 g – 250 g (~ 8weeks), female 
 
Mice used for screening of 117 KO vectors, described in chapter five, were maintained under 
specific pathogen-free conditions at the Welcome Trust Genome Campus Research Support Facility 
(Cambridge, UK). These animal facilities are approved by and registered with the UK Home Office. 
All procedures were in accordance with the Animals (Scientific Procedures) Act 1986. The protocols 
were approved by the Animal Welfare and Ethical Review Body of the Wellcome Trust Genome 
Campus.  
  Mice used for the exploration of host immune mechanisms and in vivo function of antibody 
in parasite control at QIMR were purchased from Australian Resource Centre (Canning Vale, 
Western Australia). Mice were housed in specific-pathogen free conditions in accordance with QIMR 
Berghofer animal ethics standards and the “Australian Code of Practice for the Care and Use of 
Animals for Scientific Purposes” (Australian National Health and Medical Research Council), and 
the experimentations were approved by the QIMR Berghofer Animal Ethics Committee (Herston, 
QLD, Australia; approval number:A1503-601M. 
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2.1.2 Parasites  
 
Parasite Description Reference 
P. berghei ANKA 
(PbA)  
 
A transgenic PbA line (231c1l) expressing 
luciferase and GFP under the control of the 
ef1-α promoter. Lethal experimental model. 
C57BL/6 mice succumb to cerebral malaria 
after approximately 1 week of infection. 
[129] 
P. chabaudi 
chabaudi AS 
(PcAS) 
A model of resolving infection. C57Bl/6J 
mice resolve infection with a standard dose 
within 15 days. 
[130] 
P. yoelii 17X non-
lethal (Py17XNL) 
Model of resolving infection. C57Bl/6J mice 
resolve infection with a standard dose by day 
30.  
[131] 
 
Aliquots of Plasmodium parasite-infected red blood cells (Stabilates) stored at -80◦C. 
 
2.2 Reagents 
2.2.1 Infections 
 
Items  Source  
5.0 mL  tubes Greiner Labortechnik (Frickenhausen, Germany) 
30.0 mL tubes Sarstedt (Pookara, Australia) 
Haemocytometer Pacific Laboratory Product (Blackburn, VIC, Aus) 
Immersion oil   Merck (Darmatadt, Germany) 
CliniPure Haem Kwik Fixative Grale Scientific (Ringwood, VIC, Aus) 
CliniPure Haem Kwik Stain No 1 Grale Scientific (Ringwood, VIC, Aus) 
CliniPure Haem Kwik Stain No 2 Grale Scientific (Ringwood, VIC, Aus) 
Heparin 5000 IU in 5mL Pfizer (New York, NY, USA) 
Trypan Blue 0.4% Thermo Fischer Scientific 
Sodium chloride 0.9% Baxter (Toongabbie, NSW, Aus) 
1mL Syringe Terumo (Tokyo, Japan) 
26 G needle Terumo (Tokyo, Japan) 
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2.2.2 CTFR-labelling of pRBCs 
 
Items  Source  
CellTrace™ Far Red (CTFR) Life Technologies 
DMSO Life Technologies 
DPBS Pacific Laboratory Product (Blackburn, VIC, Aus) 
5mL  tubes Greiner Labortechnik (Frickenhausen, Germany) 
50mL  Falcon Greiner Labortechnik (Frickenhausen, Germany) 
 
2.2.3 Plasmodium-specific ELISA 
 
Reagent Source 
 
Corning Costar Flat bottom 96-well plates 
 
Greiner  Labortechnik (Frickenhausen, 
Germany) 
 
OPD 
 
Sigma Aldrich Pty Ltd (St Louis 
Missouri, USA) 
 
Tween 20 
 
Sigma Aldrich Pty Ltd (St Louis 
Missouri, USA) 
 
Streptavidin-HRP 
 
BD Biosciences  (Franklin Lakes, NJ, USA) 
 
Anti- IgG 
Jackson ImmunoResearch (West Grove, 
PA, USA) 
 
2.2.4 Complement component 3 ELISA 
 
Reagent Source 
Corning Costar Flat bottom 96-well plates Greiner       Labortechnik       (Frickenhausen, 
Germany) 
OPD Sigma Aldrich Pty Ltd (St Louis Missouri, 
USA) 
Tween 20 Sigma Aldrich Pty Ltd (St Louis Missouri, 
USA) 
15 
 
Streptavidin-HRP BD Biosciences  (Franklin Lakes, NJ, USA) 
Goat IgG Fraction to Mouse Complement C3  MP Biomedicals, USA 
Peroxidase-Conjugated Goat IgG Fraction to 
Mouse Complement C3,  
MP Biomedicals, USA 
 
 
2.2.5 Surface and intracellular immune staining of pRBCs  
 
 
Reagent Source 
 
Falcon U-bottom 96-well plates 
 
Corning Incorporated- Life sciences, USA 
 
BD Cytofix/Cytoperm™ 
Fixation/Permeabilization Solution 
 
Fisher Scientific 
 
Anti-RBC antibody 34-3C (1.5µg/mL)  
Abcam, Cambridge, MA, USA). 
 
PE-Goat anti-IgG  BioLegend, San Diego, CA 92121 
 
2.2.6 Oligonucleotides used for barcode amplification and illumina sequencing 
Barcodes - a short nucleotide sequence that were inserted in the backbone of each knock-out 
vector construct to represent a particular knock-out gene. The presence of barcodes in the blood and 
tissues DNA were quantified by polymerase chain reaction (PCR) amplification, with an index primer 
used to tag each sample for individual identification and then samples were sequenced by next-
generation sequencing for barcode counting analysis.  
1st PCR primers 
Primer arg 91_Illumina TCGGCATTCCTGCTGAACCGCTCTTCCGATCTGTAATTCGTGCGCGTCAG 
Primer arg97_Illumina ACACTCTTTCCCTACACGACGCTCTTCCGATCTCCTTCAATTTCGATGGGTAC 
Illumina adapter 
PE 1.0 Primer_Illumina PCR AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCG
ATC*T  
Index tags 
iPCRindex1 CAAGCAGAAGACGGCATACGAGATTGCTAATCACTGAGATCGGTCTCGGCATT
CCTGCTGAACCGCTCTTCCGATC*T 
iPCRindex2 CAAGCAGAAGACGGCATACGAGATTAGGGGGATTCGAGATCGGTCTCGGCATT
CCTGCTGAACCGCTCTTCCGATC*T 
iPCRindex3 CAAGCAGAAGACGGCATACGAGATAGTTTCCCAGGGAGATCGGTCTCGGCATT
CCTGCTGAACCGCTCTTCCGATC*T 
iPCRindex4 CAAGCAGAAGACGGCATACGAGATCCTGGGAGGTAGAGATCGGTCTCGGCATT
CCTGCTGAACCGCTCTTCCGATC*T 
iPCRindex5 CAAGCAGAAGACGGCATACGAGATATACCACAAATGAGATCGGTCTCGGCATT
CCTGCTGAACCGCTCTTCCGATC*T 
iPCRindex6 CAAGCAGAAGACGGCATACGAGATGATCTCTCGGGGAGATCGGTCTCGGCATT
CCTGCTGAACCGCTCTTCCGATC*T 
16 
 
iPCRindex7 CAAGCAGAAGACGGCATACGAGATACCCTATACTCGAGATCGGTCTCGGCATT
CCTGCTGAACCGCTCTTCCGATC*T 
iPCRindex8 CAAGCAGAAGACGGCATACGAGATCTCAATTAAGAGAGATCGGTCTCGGCATT
CCTGCTGAACCGCTCTTCCGATC*T 
iPCRindex9 CAAGCAGAAGACGGCATACGAGATCGACAGAACGTGAGATCGGTCTCGGCATT
CCTGCTGAACCGCTCTTCCGATC*T 
iPCRindex10 CAAGCAGAAGACGGCATACGAGATTCGCCATTATGGAGATCGGTCTCGGCATT
CCTGCTGAACCGCTCTTCCGATC*T 
iPCRindex11 CAAGCAGAAGACGGCATACGAGATATGTTCCGGCCGAGATCGGTCTCGGCATT
CCTGCTGAACCGCTCTTCCGATC*T 
iPCRindex12 CAAGCAGAAGACGGCATACGAGATTCTTGAAGTGAGAGATCGGTCTCGGCATT
CCTGCTGAACCGCTCTTCCGATC*T 
iPCRindex13 CAAGCAGAAGACGGCATACGAGATGAAGGCCAGCTGAGATCGGTCTCGGCATT
CCTGCTGAACCGCTCTTCCGATC*T 
iPCRindex14 CAAGCAGAAGACGGCATACGAGATCCAATGTGCAGGAGATCGGTCTCGGCATT
CCTGCTGAACCGCTCTTCCGATC*T 
iPCRindex15 CAAGCAGAAGACGGCATACGAGATATCGAAGGACCGAGATCGGTCTCGGCATT
CCTGCTGAACCGCTCTTCCGATC*T 
iPCRindex16 CAAGCAGAAGACGGCATACGAGATTCGGGTGCGAAGAGATCGGTCTCGGCATT
CCTGCTGAACCGCTCTTCCGATC*T 
iPCRindex17 CAAGCAGAAGACGGCATACGAGATGTAATTTACGGGAGATCGGTCTCGGCATT
CCTGCTGAACCGCTCTTCCGATC*T 
iPCRindex18 CAAGCAGAAGACGGCATACGAGATATATCGACTACGAGATCGGTCTCGGCATT
CCTGCTGAACCGCTCTTCCGATC*T 
iPCRindex19 CAAGCAGAAGACGGCATACGAGATTGATTCTTACAGAGATCGGTCTCGGCATT
CCTGCTGAACCGCTCTTCCGATC*T 
iPCRindex20 CAAGCAGAAGACGGCATACGAGATACGGCGGGCCTGAGATCGGTCTCGGCATT
CCTGCTGAACCGCTCTTCCGATC*T 
iPCRindex21 CAAGCAGAAGACGGCATACGAGATCTTGCGTGGAGGAGATCGGTCTCGGCATT
CCTGCTGAACCGCTCTTCCGATC*T 
iPCRindex22 CAAGCAGAAGACGGCATACGAGATTAATCAAAGACGAGATCGGTCTCGGCATT
CCTGCTGAACCGCTCTTCCGATC*T 
iPCRindex23 CAAGCAGAAGACGGCATACGAGATGGCGGGCTCTAGAGATCGGTCTCGGCATT
CCTGCTGAACCGCTCTTCCGATC*T 
iPCRindex24 CAAGCAGAAGACGGCATACGAGATCCTCCATTTCTGAGATCGGTCTCGGCATT
CCTGCTGAACCGCTCTTCCGATC*T 
iPCRindex25 CAAGCAGAAGACGGCATACGAGATAACCAGCGCTGGAGATCGGTCTCGGCATT
CCTGCTGAACCGCTCTTCCGATC*T 
iPCRindex26 CAAGCAGAAGACGGCATACGAGATTATTCGTCAACGAGATCGGTCTCGGCATT
CCTGCTGAACCGCTCTTCCGATC*T 
iPCRindex27 CAAGCAGAAGACGGCATACGAGATGCGCTGATGCAGAGATCGGTCTCGGCATT
CCTGCTGAACCGCTCTTCCGATC*T 
iPCRindex28 CAAGCAGAAGACGGCATACGAGATCTCATATGGCTGAGATCGGTCTCGGCATT
CCTGCTGAACCGCTCTTCCGATC*T 
iPCRindex29 CAAGCAGAAGACGGCATACGAGATACAGGGGCAGGGAGATCGGTCTCGGCAT
TCCTGCTGAACCGCTCTTCCGATC*T 
iPCRindex30 CAAGCAGAAGACGGCATACGAGATGGTTTTATACCGAGATCGGTCTCGGCATT
CCTGCTGAACCGCTCTTCCGATC*T 
iPCRindex31 CAAGCAGAAGACGGCATACGAGATGCATGACTTTAGAGATCGGTCTCGGCATT
CCTGCTGAACCGCTCTTCCGATC*T 
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iPCRindex32 CAAGCAGAAGACGGCATACGAGATTTCTGAGTTCTGAGATCGGTCTCGGCATT
CCTGCTGAACCGCTCTTCCGATC*T 
iPCRindex33 CAAGCAGAAGACGGCATACGAGATCGATTAAGCTGGAGATCGGTCTCGGCATT
CCTGCTGAACCGCTCTTCCGATC*T 
iPCRindex34 CAAGCAGAAGACGGCATACGAGATTCTCTTAAGCCGAGATCGGTCTCGGCATT
CCTGCTGAACCGCTCTTCCGATC*T 
iPCRindex35 CAAGCAGAAGACGGCATACGAGATCCGACAGGTGAGAGATCGGTCTCGGCATT
CCTGCTGAACCGCTCTTCCGATC*T 
iPCRindex36 CAAGCAGAAGACGGCATACGAGATAGTATCACTATGAGATCGGTCTCGGCATT
CCTGCTGAACCGCTCTTCCGATC*T 
iPCRindex37 CAAGCAGAAGACGGCATACGAGATGTTCGCTGATGGAGATCGGTCTCGGCATT
CCTGCTGAACCGCTCTTCCGATC*T 
iPCRindex38 CAAGCAGAAGACGGCATACGAGATTCCCATGGCGCGAGATCGGTCTCGGCATT
CCTGCTGAACCGCTCTTCCGATC*T 
iPCRindex39 CAAGCAGAAGACGGCATACGAGATGGAGTTCAACAGAGATCGGTCTCGGCATT
CCTGCTGAACCGCTCTTCCGATC*T 
iPCRindex40 CAAGCAGAAGACGGCATACGAGATACTGCGTATATGAGATCGGTCTCGGCATT
CCTGCTGAACCGCTCTTCCGATC*T 
iPCRindex41 CAAGCAGAAGACGGCATACGAGATTACGTCGTGCGGAGATCGGTCTCGGCATT
CCTGCTGAACCGCTCTTCCGATC*T 
iPCRindex42 CAAGCAGAAGACGGCATACGAGATCCTTCTGTCCCGAGATCGGTCTCGGCATT
CCTGCTGAACCGCTCTTCCGATC*T 
iPCRindex43 CAAGCAGAAGACGGCATACGAGATATACTTGTTAAGAGATCGGTCTCGGCATT
CCTGCTGAACCGCTCTTCCGATC*T 
iPCRindex44 CAAGCAGAAGACGGCATACGAGATTACCCAGGAGTGAGATCGGTCTCGGCATT
CCTGCTGAACCGCTCTTCCGATC*T 
iPCRindex45 CAAGCAGAAGACGGCATACGAGATGGGGTTTTCTGGAGATCGGTCTCGGCATT
CCTGCTGAACCGCTCTTCCGATC*T 
iPCRindex46 CAAGCAGAAGACGGCATACGAGATACTGCTCGTGCGAGATCGGTCTCGGCATT
CCTGCTGAACCGCTCTTCCGATC*T 
iPCRindex47 CAAGCAGAAGACGGCATACGAGATGAAGCATAATAGAGATCGGTCTCGGCATT
CCTGCTGAACCGCTCTTCCGATC*T 
iPCRindex48 CAAGCAGAAGACGGCATACGAGATATACAGTCGCTGAGATCGGTCTCGGCATT
CCTGCTGAACCGCTCTTCCGATC*T 
iPCRindex49 CAAGCAGAAGACGGCATACGAGATCTGTCGCAAGGGAGATCGGTCTCGGCATT
CCTGCTGAACCGCTCTTCCGATC*T 
iPCRindex50 CAAGCAGAAGACGGCATACGAGATTGCAATCTAACGAGATCGGTCTCGGCATT
CCTGCTGAACCGCTCTTCCGATC*T 
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2.3 Media and stock solutions 
 
RPMI/PS: 10.0 mL penicillin; 1.0 L RPMI prepared in-house by QIMRB core services  
PBS: Prepared in-house by QIMRB core services  
5% sucrose water: 5.0 gm sucrose; 100.0 mL sterile milli-Q water 
0.2mg/mL Anhydrotetracycline hydrochloride (ATc):  Anhydrotetracycline hydrochloride (ATc) 
Sigma-Aldrich   20.0 mg; 2.6 mL of absolute ethanol; 100.0 mL of 5% sucrose water of ATc and 
dissolve in 2.6 mL ethanol to prepare ATc stock concentration 7.5 mg/mL. 
FACS Buffer: Bovine serum albumin (BSA) (Life Technology) 100g/L; 10%w/v Sodium Azide 
1mL/L; 0.5M EDTA in PBS pH8 (Sigma) 10mL/L; 1L PBS; filtered and de-gassed through 0.2 μm 
bottle-top filter at 4oC for 20 minutes.  
FACS Block: Generated in-house by harvesting supernatant of 120/G8 hybridoma to block Fc 
receptor.  
4% PFA: Paraformaldehyde powder (MP Biomedicals, USA) 4.0 g/100mL; PBS 100 mL; added 
~20μL NaOH while gently heating and stirring until powder dissolves. Add HCL until pH is 7. 
Aliquots of this were stored at -20oC until use. 1-2% PFA was made with the addition of PBS just 
prior to use.  
1.6% saline (w/v): 1.6g of NaCl in 100.0 mL sterile milli-Q water  
12% saline (w/v): 12g of NaCl in 100.0 mL sterile milli-Q water  
33% percoll: 1:3 v:v of Percoll in PBS  
ELISA bicarbonate coating buffer: 1.0 L PBS; 1.59 g Na2CO3; 2.93 g NaHCO3; pH adjusted to 
9.6; filtered  
ELISA blocking buffer: 1.0 L PBS; 1% BSA; 0.05% Tween 20; filtered.  
ELISA wash buffer: 0.5 mL Tween20; 1.0L PBS.  
PcAS and Py17XNL antigens: prepared in house. 
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2.4 Methods  
2.4.1 Setting up passage mice with parasitized RBCs 
Non-lethal Py17XNL and PcAS parasites were used after a single in vivo passage in wild type 
C57BL/6 mice. In order to conduct this procedure, 350 µl of the frozen stabilates were firstly thawed 
at room temperature – one fifth the blood volume of sterile 12% NaCl (w/v) (BDH Chemicals, 
Kilsyth, Victoria, Australia) was then added in drops into each thawed stabilate and incubated on ice 
for five minutes. RBCs were transferred into a 10 mL falcon tube and washed in ten times the blood 
volume of 1.6% NaCl (w/v) at 1200 rpm for 10 minutes at room temperature (RT). Supernatants were 
discarded and RBCs were then resuspended in 1.0 mL of sterile PBS. 200 ul of this preparation was 
then injected intravenously (i.v) into naive mice. Parasitemia was assessed on day 4 post-infection - 
mice were culled and used in subsequent procedures if the parasitemias were between 1-5%. In some 
experiments, lethal PbANKA parasites were used following a single in-vivo passage in C57BL/6 
mice. For these passages, one vial containing approximately 350 µl of frozen PbANKA parasites was 
thawed, and 200 µl of this was injected via intraperitoneal (i.p.) route into C57BL/6 mice. Similarly, 
mice were culled and used in subsequent procedures at 1-5% parasitemia. 
 
2.4.2 Infection of mice with parasitized RBCs 
Passage mice were culled by CO2 inhalation. Blood was then collected by cardiac puncture 
using an insulin syringe and washed in 10.0 mL of RPMI culture media containing heparin, penicillin 
and streptomycin, spinned at room temperature for seven minutes at 1200 rpm.Supernatants were 
discarded and pRBCs resuspended in 1.0 mL of RPMI/PS. Next, the total numbers of RBCs and 
parasitised RBCs were determined. Naive mice were infected i.v. with either 104 pRBCs (Py17XNL) 
or 105 pRBCs (PcAS) or 105 pRBCs (PbANKA). 
 
2.4.3 Cell counts 
Red and white blood cells were stained with 0.1% w/v trypan blue (Sigma, St. Louis, Mo, 
USA) in PBS and counted using a haemocytometer under x10 objective on a light microscope. Dead 
cells were excluded based on the uptake of trypan blue. Viable cells in all 25 small squares on the 
hemocytometer were counted. The total number of cells in 1.0 mL of blood was calculated as cell 
count on haemocytometer x dilution factor x 1000 (volume of blood) x volume of the chamber (104). 
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2.4.4 Preparation of crude parasite antigen 
Crude antigenic extract from Py17XNL or PcAS-infected RBCs was prepared using an 
adapted version of a previously described protocol [132, 133]. Briefly, mice were infected with 
Py17XNL or PcAS as described above. When parasitaemia reached 20-30%, blood was collected by 
cardiac puncture into heparinized tubes. RBCs were washed once in RPMI at 1200xg for 7 minutes 
at room temperature, and then lysed using ultrapure water followed by four washes in ice-cold PBS 
at 16,000xg for 25 minutes at 4oC, and three cycles of freezing (2 hours at -80oC) and thawing (30 
minutes at room temperature). Extracts were also processed from RBCs of uninfected C57BL/6 mice 
for use as negative controls in ELISA. All extracts were stored at -80oC until their use. These are the 
whole parasite crude antigens. 
 
2.4.5 Quantification of protein concentration 
The concentration of proteins in the purified extracts was determined by Bradford assay 
(Thermo scientific) according to the manufacturer’s instructions. Briefly, two microliters of a serially 
diluted test sample or bovine serum albumin (BSA) (Sigma) proteins were added into a 96 well flat-
bottomed tissue culture plate (Becton Dickinson Labware) that contained 200 µl per well of the 
protein assay reagent. Absorbance at 595 nm was read on a Biotek synergy H4 ELISA plate reader 
(Biotek, USA) and the concentration of the test sample calculated from the BSA protein standard 
curve. 
 
2.4.6 Generation of immune serum 
C57BL/6 mice were immunized against Plasmodium yoelli 17XNL, Plasmodium chabaudi 
chabaudi AS infection to generate immune serum, while age-matched control mice were maintained 
for non-immune serum. Passage mice were sets from a frozen stabilates (infected red blood cells) 
prior to infection. Mice were infected intravenously via a lateral vein with 1 x 104 (Py17XNL) or 1 x 
105 (PcAS and PbA) freshly prepared parasitized RBCs (pRBCs). Parasitemia was monitored at 
different days post infection until resolution of infection. Parasite-specific antibody titer was 
measured before collecting cardiac blood to generate serum. Once parasite-specific antibody titer was 
reached a steadily state achieved then the mice were euthanized by CO2 inhalation. Whole blood was 
collected via cardiac bleed using a 26 gauge insulin syringe with a needle into an eppendorf tube for 
serum collection. Prior to serum separation blood tubes were incubated at room temperature for 1 
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hour and then overnight at 4oC. The blood samples were then centrifuged at 13000xg for 10 minutes 
at room temperature (RT) and serum was collected and sorted at -80oC prior to use.   
 
2.4.7 CellTraceTM Far Red (CTFR) labelling and adoptive transfer of donor pRBCs 
Rodent malaria parasite-specific infected red blood cells were passaged through C57BL/6J 
mice prior to being used. Passage mice were selected for cardiac bleed when parasitemia of passage 
mice reached around 5% with mostly ring stage parasite life-cycle stages present. Whole blood was 
collected by cardiac bleed using a 26-gauge insulin syringe with a needle into 5mL RPMI/PS 
containing 5U/mL heparin sulphate. Heparinised donor blood containing pRBCs was washed twice 
in Ca2+/Mg2+-free phosphate buffered saline (PBS-A) at 1200xg for 10 mins at room temperature, 
then blood was resuspended in 5 mL PBS-A. A 50μg vial CellTraceTM Far Red (CTFR) was dissolved 
in 25µl of dimethyl sulphoxide (DMSO) for 10 mins prior to mixing with 5mL of resuspended RBC 
and then incubated for 20 minutes at room temperature on the roller. Cells were washed twice in 10x 
volume of PBS-A. Successful CTRF labeling of RBCs was confirmed by flow cytometry using a 
LSRII Fortessa analyzer (BD Biosciences) and Flowjo software (Treestar, CA, USA). CTFR-labelled 
RBC was resuspended in 2mL volumes per donor mouse, and injected in 200µl volumes via 
intravenous injection (i.v) using 26G needles. 
 
2.4.8 in vivo Clearance/Growth Assay 
In this thesis, I have used established mouse models of blood-stage Plasmodium infection to 
explore how parasites circulating in the bloodstream may be controlled by the host.  Most importantly, 
I employed and further modified an RBC adoptive transfer approach developed in our laboratory to 
examine parasite clearance and replication in vivo. Hereafter I refer to this assay as the 
“Clearance/Growth” assay. This assay entails the study of a fluorescently-labeled single generation 
of infected parasitised RBC by flow cytometry [134]. In this assay, donor RBCs (including infected 
and uninfected RBCs) are labeled with fluorescent dye CellTrace™ Far-Red (CTFR), referred to as 
Generation 0 (Gen0), and intravenously injected into recipient mice. Gen0 pRBC were then tracked 
over time to observe the development of the parasites within the donor RBCs and their subsequent 
rupture and re-appearance as parasite progeny in recipient (ie. unlabelled) RBCs, referred to as 
Generation 1 (Gen1 pRBC).  
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Figure 2.1 Clearance/Growth assay. PbGFP-infected cardiac blood was labelled with CellTrace™ 
Far-Red (CTFR) washed and injected into recipient mice. Tail bleeds of recipient mice were done at 1-
97 h.p.i and parasitemia measured by flow cytometry. 
 
2.4.9 Flow cytometric based quantification of parasitized RBCs 
A modified protocol of a previously established flow cytometric method was employed to 
measure parasitemia more rapidly [135]. Briefly, a single drop of blood, from a tail bleed or cardiac 
puncture, was diluted and mixed in 250μl RPMI containing 5U/mL heparin sulphate. Diluted blood 
was simultaneously stained with Syto 84 (5μM; Life Technologies) to detect RNA/DNA, and Hoechst 
33342 (10μg/mL; Sigma) to detect DNA, for 30 minutes, in the dark at room temperature. Staining 
was quenched with 10x volume of ice-cold RPMI, and samples were immediately analysed by flow 
cytometry, using a BD FACS CantoII analyser (BD Biosciences) and FlowJo software (Treestar, CA, 
USA). pRBC were readily detected as being Hoechst33342+ Syto84+, with white blood cells 
excluded on the basis of size, granularity, and much higher Hoechst33342/Syto84 staining compared 
to pRBC. Parasitemias were routinely measured daily for up to 50 days post infection. 
 
2.4.10 Depletion of phagocytes 
Mouse phagocytes including macrophages, monocytes, and dendritic cells were depleted with 
a single intravenous injection of a 200 µl volume of clodronate-containing liposomes 
(www.clodronateliposomes.com)  via a lateral tail vein using 26G needles 3 days prior to infection 
[136, 137]. 
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2.4.11 Depletion of complement factors C3/C5 
To deplete mice of the complement components C3/C5, 10µg of Cobra Venom Factor (CVF) 
(Quidel) was injected intraperitoneally 16 hr prior to infection (day -1), and then daily on days +1, 
+2 and +3; control mice were injected with saline. To evaluate the efficacy of CVF treatment, C3 
depletion efficacy was measured in serum by sandwich enzyme-linked immunosorbent assay 
(ELISA). Costar EIA/RIA 96-well flat bottom plates were coated overnight at 4oC with 2.0µg/mL 
primary antibody (Goat IgG Fraction to Mouse Complement C3, MP Biomedicals) in PBS. Wells 
were washed three times (all washes in 0.005% Tween in PBS) and then blocked for 1 hr at room 
temperature (RT) with 1% BSA in PBS. Wells were washed three times, and 100μl of sera in duplicate 
at 1/9000 and 1/27000 was added and incubated for 1 hr at RT. Following six washes, wells were 
incubated in the dark with a secondary antibody (Peroxidase-Conjugated Goat IgG Fraction to Mouse 
Complement C3, MP Biomedicals) for 1hr at RT. Unbound antibodies were washed off six times 
prior to incubating wells in the dark with streptavidin HRP (BD Biosciences) for 30 mins at RT. Wells 
were washed six times prior to development with the substrate (OPD; Sigma-Aldrich) for five minutes 
in the dark before termination with 1M HCl. Absorbance was determined at 492nm using Biotek 
synergy H4 ELISA plate reader (Biotek, USA).  
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2.4.12 In vivo and in vitro staining of pRBCs with antibodies in immune serum with/without 
permeabilisation  
In vivo and in vitro staining of pRBCS was done in diluted blood collected from infected mice 
receiving immune serum, non-immune serum or no serum. Briefly, diluted blood was incubated 
with/without anti-RBC antibody 34-3C as primary antibody (1.5µg/mL; ab109101). Cells were 
washed three times in FACS buffer (1% w/v BSA (Life technologies), 5mM EDTA in PBS) prior to 
incubation with secondary antibody FITC Goat anti-mouse IgG ( 3µg/mL; Biolegend, San Diego, 
CA). In order to fix and permeabilise the pRBCs, diluted blood was mixed with cytofix buffer (BD 
Cytofix/Cyto permTM solution kit from BD Life Sciences) at 1:1 volume and then incubated with anti-
RBC antibody 34-3C (1.5µg/mL) and immune and non-immune serum in 1X cytoperm buffer. Cells 
were washed in 1X cytoperm buffer (BD Life Sciences) prior to incubation with secondary antibody 
FITC-goat anti-mouse IgG (3µg/mL). Then cells were stained with cell-permeant RNA/DNA stain, 
Syto™ 84 (5 μM; Life Technologies) and with DNA stain, Hoechst 33342 (10 μg/mL; Sigma). 
Staining was quenched with 10 volumes of ice-cold RPMI medium, and samples were analysed 
immediately by flow cytometry using a LSRII Fortessa analyser (BD Biosciences) and FlowJo 
software (Treestar, CA, USA).   
2.4.13 Estimation of Plasmodium-specific immunoglobulins in serum by ELISA  
Costar EIA/RIA 96-well flat bottom plates were coated overnight at 4oC with 100μL/well of 
2.5μg of soluble antigen/mL in bicarbonate coating buffer. Wells were washed three times (all washes 
in 0.005% Tween in PBS) and then blocked for 1hr at 37oC with 1% BSA in PBS (Blocking buffer). 
Wells were washed three times and 100μL of sera diluted to 1/400, 1/800, 1/1600 or 1/3200 was 
added before being incubated for one hour at 37oC. Following six washes, wells were incubated in 
the dark with biotinylated anti-total IgG for one hour at room temperature. Unbound antibodies were 
washed off (six times) prior to incubation with streptavidin HRP in the dark for 30 minutes at room 
temperature. Wells were washed six times and developed with 100μL of OPD for 3-5 minutes in the 
dark before termination with an equal volume of 1M HCl. Absorbance was determined at 492nm 
using a Biotek synergy H4 ELISA plate reader (Biotek, USA). Data were analysed using Gen5 
software (version 2) and GraphPad Prism (version 6). 
 
2.4.14Preparation of vector DNA for transfection 
To minimise expenses and labour in DNA production, a pooled midiprep procedure was 
adopted to produce the DNA for transfection in P. berghei experiments. Vectors were generated using 
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a 96-well method (detailed protocol described in [138]). Vectors were inoculated from a master plate 
of glycerol stocks (-80oC) in 1 mL of TB-kan (30 µg/mL kanamycin) in a 96-deep well plate and 
incubated overnight at 37oC with shaking. For each transfection, two wells were inoculated with each 
vector to be used in an experiment. Following the overnight incubation, all wells from a single 
experiment were pooled together and then processed with a QIAFilter Midi kit (according to 
manufacturer’s instructions, however using 2x volumes of P1, P2 and P3 due to the use of a low copy 
vector). The resulting DNA was spiked with additional DNA for 7 reference vectors (prepared by 
Ana Rita Gomes) – 4 redundant in the blood stages: p25, p28, soap, p230p; and three known to result 
in attenuated growth: plasmepsin IV, methyltransferase-like protein, putative and oxoisovalerate 
dehydrogenase subunit beta, mitochondrial, putative (BCKDHB). The use of these universal 
reference vectors allowed the calibrated comparison of all PlasmoGEM barseq experiments. The 
pooled DNA was digested then with NotI, precipitated with isopropanol and resuspended in 6 μl TE 
buffer in preparation for transfection.  
 
2.4.15 Schizont preparation and transfection 
Plasmodium berghei was isolated from thicket rats of central Africa as these animals are one 
of the natural hosts for this rodent malaria parasite.  For in vitro schizont cultures, parasites were first 
passaged into female Wistar rats to achieve maximal transfection efficiency. A female Wistar rat was 
infected by intraperitoneal (i.p) injection and monitored until blood parasitemia reached 1-3%. 
Infected blood was then harvested by cardiac puncture and prepared as a schizont culture: 25x blood 
volume schizont medium (RPMI 1640 supplemented with 25mM L-glutamine, 25mM HEPES, 
10mM NaHCO3, 100 U/mL penicillin/streptomycin and 25% fetal bovine serum) was added and the 
flask gassed for 90 seconds with malaria gas mixer (1% O2, 3% CO2, 96% N2) before incubating 
overnight with shaking. The next day, smeared thin blood film was prepared from the culture to check 
for the presence of mature schizonts and these were purified on a 55% Nycodenz/PBS (v/v) cushion 
with low brake. The schizont-containing interface was collected with a Pasteur pipette and washed 
with schizont medium. Schizonts were pelleted by centrifugation (at 500 x g for 2 mins), and the 
pellet resuspended in 16 μl P3 solution (Lonza). The 6 μl vector pool was then added to this mixture 
and transfection was carried out in 16-well Lonza cuvette strips with the programme, FI-115. The 
transfection mixture was immediately injected intravenously into the tail veins of 6-8 week old, 
C57BL/6 (B6), rag1-/-, Balb/c and SCID mice. The next day, drinking water was supplemented with 
pyrimethamine to begin selection (0.7 mg/mL). 
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2.4.16 Blood DNA extraction by phenol-chloroform methods 
DNA was purified by phenol-chloroform extraction for a maximal yield of DNA from low 
parasitemia samples. Red blood cells were lysed by adding 10 pellet volumes of ammonium chloride 
lysis buffer 0.15M NH4Cl, 0.01M KHCO3, 1mM Na2EDTA; pH 7.4) and incubating on ice for 5 
minutes. The lysate was centrifuged (at 5000xg for 5 mins) and the parasite pellet resuspended in 500 
μl TNE buffer (50mM Tris-HCl, 100mM NaCl, 5mM EDTA; pH 8.0). Two l of RNase A 
(20 mg/mL) and 55 l of 10 % SDS was added to the resuspended pellet and incubated for 10 minutes 
at 37C. Subsequently, 10 l of proteinase K (20 mg/mL) was added and the mixture was vortexed 
and incubated at 37 C for 30 minutes. The lysate was combined with 500 μl of 25:24:1 
phenol:chloroform:isoamyl alcohol, mixed by thorough shaking and then centrifuged for (at 10000g 
for 5 mins). The aqueous supernatant was transferred to a new tube and 500 μl of chloroform-isoamyl 
alcohol was added. The tube was mixed thoroughly and then centrifuged (at 10000g for 5 mins). The 
aqueous phase was transferred to a new tube, 3μl of pellet paint (co-precipitant) was added and the 
DNA was precipitated overnight at -20oC after the addition of 500 μl isopropanol. The isopropanol 
was then removed and the pellet dried and then resuspended in 50 μl or 100 μl of TE buffer.  
 
2.4.17 Perfusion, organ harvest and genomic DNA extraction 
On day 7 post-infection, mice were terminally anesthetised, perfused and organs (including 
spleen, lung, heart, brain, liver, kidney and adipose tissue) were collected. Each tissue sample was 
weighed and preserved at -80oC prior to DNA extraction. Samples were mashed using a tissue 
homogenizer in 500µl PBS and 100µl of mashed tissue (for spleen 50µl) used for DNA extraction 
using Qiagen DNeasy Blood and Tissue kit (according to the manufacturer’s instructions). 
 
2.4.18 Barcode amplification  
PCR was used to amplify barcodes from the extracted genomic DNA. A 50μl Advantage 2 
Polymerase reaction was prepared, according to the manufacturer’s instructions, with the primers, 
arg91 and arg97 [139]. One μl (5-7ng) of phenol-chloroform extracted gDNA was used as the 
template for the reaction. The protocol for the PCR was as follows: 95oC 5’ //95o C 30” / 55o C 20” / 
68o C 8” (x35) // 68o C 10’ //. Barcodes were amplified in parallel from a final sample to yield the 
‘input pool’ i.e. the DNA used for transfection. This parallel amplification was important to ensure 
that absence of a barcode in the population was not due simply to a failure of the bacteria carrying 
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that vector to grow. 5 μl of the product from the first PCR reaction was used as the template for a 
subsequent PCR reaction, in which Illumina adapters were added (to adhere the product to the 
Illumina flow cell), and index tags were inserted (to allow the sample corresponding to each read to 
be determined after sequencing). The PCR parameters were as follows:  
95o C 5’ // 95o C 30” / 68o C 15”(x10) // 68o C 5’ // 
Following the second PCR, DNA was purified using a QIAGEN MinElute PCR purification kit. 
Eluted DNA was quantified using the Qubit system and 100 ng of each sample was taken and pooled 
together. Up to 48 samples were sequenced per run of the Illumina sequencer. A water control was 
used throughout the entire experiment to ensure that reagents were not contaminated with trace 
amounts of barcodes. 
2.4.19 Barcode sequencing 
Due to their low complexity, PCR amplicon libraries were further diluted to 1nM and then 
spiked with 40-50% of PhiX before being loaded at a low cluster density (4 x105 clusters/mm2). All 
samples were loaded and run on a MiSeq instrument by the low-throughput Illumina. Reads were 
paired-end and 150 nucleotides in length collected. These steps were conducted by the Sanger 
Institute Illumina C team.      
 
Figure 2.2 Schematic of the barcode module illustrating primer annealing sites and amplification 
steps. 
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2.4.20 Analysis of barcode-based sequencing data  
Using a Perl script written by Frank Schwach, barcode sequences were extracted from the 
sequencer output files (fastq) and total numbers of  barcodes (b) for each gene (g), for every time 
point (d, 4-7), for each mouse (m, 1-3) was calculated, (i.e.,  𝒃𝒅, 𝒎, 𝒈). This was also calculated for 
the input samples. 
The relative abundance (p, proportion) of each barcode (𝒑 𝒅, 𝒎, 𝒈) within the pool was then 
determined by dividing the number of barcodes of each gene by the sum of barcodes for all genes of 
each sample (represented by the index tag), i.e. 
𝒑 𝒅, 𝒎, 𝒈 =
𝒃𝒅, 𝒎, 𝒈
∑ 𝒃, 𝒅, 𝒎, 𝒈𝑮𝒏𝑮𝟎
 
Note: The quantification was considered reliable for barcodes accounting for at least 0.1% of all 
counts. 
The daily fold-change (c) of the relative abundance of each mutant (𝒄𝒅, 𝒎, 𝒈 ) was determined by 
dividing the relative abundance of each mutant on a particular day by the relative abundance of that 
mutant on the previous day, i.e.: 
𝒄𝒅, 𝒎, 𝒈 =
𝒑𝒅 + 𝟏𝒎, 𝒈
𝒑𝒅, 𝒎, 𝒈
 
The relative fitness (f) of a mutant (𝒇𝒅, 𝒎, 𝒈)  was calculated by normalizing the fold-change of a 
mutant using the mean fold-change of the reference mutants (
𝟏
𝒏
  ∑ 𝑪𝒅, 𝒎, 𝑹𝒏𝑹𝒏𝑹𝟎 ) . 
 
              𝒇𝒅, 𝒎, 𝒈 =
𝑪𝒅,𝒎,𝒈
𝟏
𝒏
  ∑ 𝑪𝒅,𝒎,𝑹𝒏𝑹𝒏𝑹𝟎
 
Note:  Barcode sequencing analysis of the blood samples was based on the fitness value at Day 7, 
whereas for the tissue sample was based on relative abundance at Day 7.  
2.4.21Statistical analysis 
Comparisons between two groups were performed using non-parametric Mann-Whitney 
(unpaired datasets or Wilcoxon (paired datasets) tests. Where depicted, one-way or two-way ANOVA 
and Tukey’s post-test were employed for multiple comparisons among three or more groups. p<0.05 
was considered significant (p<0.05=*; p<0.01=**; p<0.001=***; P<0.0001=****). Graphs depict 
mean values (SEM), except where individual mouse data points are depicted, in which case median 
values are shown. All statistical analyses were performed using GraphPad Prism 6 software. 
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Chapter Three: 
Exploring mechanisms of parasite control during blood-stage Plasmodium 
infection 
3.1 Abstract  
Symptoms of malaria occur during the blood-stage of infection and can vary from 
asymptomatic infections to life-threatening syndromes such as cerebral malaria. Disease severity 
often correlates with the number of blood-stage parasites in the body. It is likely that both host and 
parasite factors are involved in determining parasite growth kinetics in vivo. However, our 
understanding of these factors is incomplete. Given that an effective malaria vaccine currently 
remains elusive, and that resistance has emerged against the currently available anti-malarial drugs, 
it is important to identify new approaches for controlling the number of parasites in vivo.  
Here, I have used experimental mouse models of blood-stage Plasmodium infection to directly 
measure parasite maturation, clearance and replication rates in vivo. I observed that parasite control 
can be achieved in a number of ways including (i) anti-malarial drugs that inhibit or arrest parasite 
development within a red blood cell, (ii) drugs that prevent parasites from progressing from one 
generation of red blood cells to another, (iii) by host phagocytes actively removing parasitised red 
blood cells, and (iv) by host-mediated impairment of parasite maturation within red blood cells. 
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3.2 Introduction 
Blood-stage malaria initiates once the merozoite form of the Plasmodium parasite invades 
host RBCs and enters the intra-erythrocytic stage of its life-cycle. This includes progression through 
ring, trophozoite and schizont stages before each parasitised RBC ruptures to release tens of daughter 
merozoites that go on to invade new RBCs. The severity of the disease, particularly elicited in humans 
by P. falciparum, strongly correlates with the total number of parasites in the body. Thus parasite 
load, disease severity and infection outcome can be considered to be determined by two opposing 
biological processes: 1) how effectively the host can control parasite numbers, and 2) how efficiently 
parasites can replicate within the host. The rate of parasite replication is dependent on multiple 
factors, such as the replication efficiency of the parasite (including the number of merozoites 
produced from each parasite, their survival capacity, and ability to invade RBC’s). The host 
mononuclear phagocytic system (MPS) is thought to play a major role in controlling infection, for 
example via removal of parasitized RBC by macrophages in the spleen and liver [86]. Similarly, 
splenic function increases during acute malaria [140, 141], and parasite clearance can be delayed in 
splenectomized patients after artesunate treatment [142]. It has been shown in animal models that the 
spleen could remove intraerythrocytic parasites leaving the RBC intact, a process called “pitting” 
[143]. Thus splenic “pitting” is thought to be a host mechanism of parasite removal. However, despite 
these reports, in vivo mechanisms of parasite clearance in blood-stage malaria remain unclear. 
Moreover, we have defined “delayed maturation” as a theoretical mechanisms by which parasites 
growth could be controlled. Parasites with delayed maturation perhaps represented drug-mediated or 
immune-damaged parasites with impaired development which occurs as a parasite survival 
mechanisms in response to environmental stress [122, 144]. 
In this chapter, I sought to investigate host mechanisms of parasite control during blood-stage 
malaria in an established mouse model, Plasmodium berghei ANKA (PbANKA) infection of 
C57BL/6J mice, both in the presence and absence of anti-malarial drugs. I have also used our 
laboratory’s unique in vivo Clearance/Growth assay to examine in detail the biology of a single cohort 
of pRBC. PbANKA infection of C57BL/6J mice is a lethal model, since it induces symptoms similar 
to those in the human severe malaria, and has been used predominantly to study pathology associated 
with cerebral malaria. [145]. However, recent reports show that in addition to cerebral symptoms, 
PbANKA infection causes widespread pathology such as liver damage, respiratory distress and 
metabolic acidosis [146-150]. Even though the pathogenesis of human severe malaria is not fully 
understood, disease severity strongly correlates with total numbers of parasites in the body, i.e., the 
sum of those circulating freely in the bloodstream and those sequestered in tissues [151]. The 
infection is typically fatal within a relatively short timeframe (approximately one week) [146].  
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Artesunate (an artemisinin derivative) is a WHO-recommended treatment for patients with 
uncomplicated malaria, due to its faster reduction in parasitemia compared to previous anti-malarials 
[22-24]. A unique feature of artesunate is that it appears to target a wide range of parasite 
developmental stages [25]. The clearance of artesunate-treated, killed or damaged parasites are 
thought to be accelerated by host immune mechanisms [122, 124]. Currently, the rate of parasite 
disappearance from circulation following drug treatment is used to detect parasite resistance to 
artemisinins [152-154]. Furthermore, it is hypothesised by some [155, 156], that the total reduction 
of parasites after drug treatment is dependent on 1) drug-mediated killing or impairment of parasite 
development [157], and 2) host-mediated clearance [126].  
Many studies have reported that the emergence of resistance in Southeast Asia is due to the 
short course of Artesunate monotherapy [26, 158]. Since artesunate is a short-acting drug, it has been 
combined with longer-acting antimalarial drugs to increase efficacy and prevent/delay the 
development of resistance. These regimens, of which there are several, are collectively termed 
Artmisinin-based Combination Therapies (ACT)[159, 160]. Artesunate-mefloquine is one of the five 
ACTs recommended by the WHO for the treatment of uncomplicated malaria (WHO 2015). Many 
studies have reported that the combination of short-acting artemisinin derivative (artesunate) with 
longer acting mefloquine is effective in the treatment of uncomplicated, multi-drug resistant malaria 
[161-163], and that mefloquine has an effect on the asexual form of the parasite (schizontocidal 
effect). Despite intensive research into anti-malarial drugs, there remains some debate regarding the 
mode of action of artemisinins. It may be beneficial to better understand mechanisms of anti-malarial 
drug action in vivo, particularly to aid the design of next-generation anti-malarial drug therapies.  
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3.3 Results 
3.3.1 Artesunate effectively controls ongoing Plasmoduim berghei ANKA (PbA) infection in vivo 
Before exploring in vivo mechanisms of action for artesunate, it was important to first confirm 
that artesunate was indeed effective in mice infected with PbANKA (PbA). To do this, mice were 
infected with PbA, and artesunate treatment was initiated 5 days post-infection when mice are known 
to exhibit signs of severe malaria such as liver damage [164] [165]. Parasitemia was measured daily 
using flow cytometry from day 0 – day 5 p.i. and every 12 h following initiation of treatment with 
200 µg doses of sodium Artesunate (i.e. 10 mg/kg, every 12h for 2.5 days) or control saline.  All mice 
in the control group (6/6) exhibited high clinical scores, requiring euthanasia between days 6-9 (6/6). 
In contrast, none of the treated mice (0/6) exhibited serious illness by day 13 (0/6), although 
parasitemia increased, as expected, once artesunate cover was removed (Figure 3.1). Thus, the data 
confirmed that artesunate was effective as a short-acting drug against PbA infection in mice, which 
permitted further studies into in vivo mechanisms of action of this anti-malarial drug. 
 
 
 
 
 
 
 
 
Figure 3.1 Effectiveness of Artesunate in vivo. The time course parasitaemia due to Plasmodium 
berghei ANKA in the saline control (black) and Artesunate-treated (red) mice analysed. C57BL/6J 
(n = 5/group) mice were infected intravenously with 1x105 pRBCs of Plasmodium berghei ANKA 
(PbA) and parasitemia was measured was measured daily beginning at the day 3 p.i., 200µg of 
Artesunate (red) or saline controls (black) was administrated for every 12h (beginning at the day 5 
p.i) for 2.5 days. Data representative of two independent experiments showing similar results. 
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3.3.2 In vivo anti-malarial drug treatment prolongs the presence of Gen0 parasites in the 
circulation 
To investigate mechanisms of action of different anti-malarial drugs, I used the in vivo 
Clearance/Growth assay, as described in detail in the Material and Methods, in which a single 
generation of fluorescently-labeled infected parasite “donor pRBCs” are infused and tracked in vivo 
[134]. This approach differentiates a single generation of parasites from their progeny, i.e. the donor 
pRBCs that we transfused into the recipient mice, which we define as Gen0, from the progeny of these 
transfused parasites in unlabelled (i.e. recipient) RBCs, defined as Gen1. We transfused mice with 
labelled Gen0 pRBCs, immediately treated with different doses of artesunate, mefloquine or control 
saline and examined Gen0 and Gen1 pRBC over time (Fig 3.2A & B). Mefloquine is thought to cause 
slower declines in parasite numbers compared to artesunate, but has a longer half-life and works by 
destroying the asexual blood form of the parasite [163]. Therefore, I examined the effects of 
mefloquine on parasite clearance (Gen0) and growth (Gen1).  
Anti-malarial drugs (artesunate and mefloquine) were effective in controlling total 
parasitemia in a dose-dependent manner (Figure 3.2C). Next, I analysed the removal of Gen0 pRBCs 
after treatment with anti-malarial drugs to measure increases in the parasite clearance due to 
treatment. In control-treated mice, Gen0 pRBCs were largely absent from the circulation by ~24 h, as 
expected, whereas artesunate or mefloquine-treated mice showed a dose-dependent increase in the 
numbers of Gen0 pRBCs remaining in the circulation (Figure 3.2D). The data indicated that artesunate 
had not accelerated the rate of removal of Gen0 pRBC, and instead had caused them to remain in 
circulation for longer (Figure 3.2E). As a result, transitioning of the parasite from Gen0 to Gen1 was 
restricted (Figure 3.2 F & G). Together, these data suggested that anti-malarial treatment caused Gen0 
parasite to remain in circulation longer than without treatment by preventing parasite transition from 
one generation to the next. 
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Figure 3.2 In vivo antimalarial treatment causes parasites to linger in the circulation. (A) Naïve 
mice were intravenously injected with fluorescently labelled P. berghei ANKA-GFP (PbG) infected 
blood were immediately treated with saline (black/grey) or 1000 µg artesunate (red), or 200 µg 
artesunate (blue), or 250mg/kg mefloquine (green), or 50 mg/kg mefloquine (pink) or 10 mg/kg 
mefloquine (purple). (B) The gating strategy identified single cells and RBCs, differentiated 
unlabelled endogenous RBC and adoptively transferred donor RBCs by fluorescent CTFR  labelling, 
identified all parasitised RBC and endogenous RBC (Gen1 pRBC) by Hoechst DNA labelling and 
GFP expression, and infected donor cells (Gen0 pRBC) and the stage of parasite maturation by 
Hoechst DNA and Syto 84 DNA/RNA labelling. (C) Total parasitaemia, (D) Representative FACS 
plots for donor Gen0 pRBC, and (E) Proportion of G0 pRBC remaining for 1-25 h.p.i (F) endogenous 
Gen1 RBC with pRBC gates are shown for 19-49 h.p.i and (G) parasitaemia of endogenous Gen1 
pRBC were calculated. Dotted lines = detection thresholds. (n = 5 per group, error bars are SEM, 
p<0.001 = ***, p<0.0001 = ****). Data representative of two independent experiments showing 
similar results. 
 
 
3.3.3 Examination of the modes of action for aresunate-mefloquine combined therapy  
Here, fluorescently labeled PbG infected blood was transferred into recipient mice and 
immediately treated with a combination of 200 μg artesunate and 50 mg/kg mefloquine, with either 
drug alone, or with vehicle alone (Figure 3.3A). All drug therapies caused Gen0 pRBC to remain in 
the circulation (Figure 3.3B & C), with artesunate-mefloquine combined treatment exhibiting the 
strongest effect. Next, I observed that mefloquine alone modestly slowed growth in Gen1 pRBC 
(Figure 3.3D). As expected, artesunate alone was effective at preventing detection of Gen1 pRBC; 
however, the combination therapy was the most efficient, demonstrating that the combined treatment 
maintained parasitemia below the level of detection, over time (Fig 3.3E).  Together, these data 
demonstrated that an established ACT regimen did not accelerate the removal of pRBC, and instead, 
served to prevent parasites transitioning from one generation of RBC to the next.   
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Figure 3.3 Combination therapy with artesunate and mefloquine had strongest effects on parasite 
persistance and growth. (A) Recipient mice were injected with fluorescent-labelled PbG infected 
blood and immediately treated with control vehicle (black/grey), 200 µg Artesunate (dark red), 50 
mg/kg Mefloquine (purple) or both the Artesunate and Mefloquine doses (royal blue). Tail bleeding 
of the recipient mice was done 1-97 h.p.i at different intervals and parasitaemia measured by flow 
cytometry. (B) Representative FACS plots showing G0 pRBC gates in vivo over time and (C) 
Proportion of G0 pRBC remaining for 1-25 h.p.i. (D) endogenous Gen1 RBC with pRBC gates are 
shown for 19-49 h.p.i and (E) parasitaemia of endogenous Gen1 pRBC were calculated.  Dotted lines 
= detection threshold. (n = 5 per group, error bars are SEM, p<0.001 = ***, p<0.0001 = ****). 
Data representative of two independent experiments showing similar results. 
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3.3.4 Splenectomy does not alter the clearance of Gen0 pRBC from the circulation 
The spleen is thought to play many important roles during malaria, in clearance of damaged 
pRBCs from circulation [126], pitting of pRBC [166], and the generation of pathogen-specific 
immune responses [reviewed in  [127, 167]. The importance of the spleen in malaria was revealed by 
studying splenectomized humans and rodents. It was suggested that splenectomized malaria patients 
had elevated parasitemias and prolonged parasite clearance times after anti-malaria treatment [126, 
168]. Further study in animal model suggests that host defense in primary malaria infection requires 
intact spleen [169-171].  However, the precise role of the spleen in clearing pRBC during malaria, 
either in the presence or absence of anti-malarial drug treatment, remains unclear. It has evidenced in 
animal models studies that spleen could remove intraerythrocytic parasites leaving host erythrocytic 
intact, a process called pitting [143] and splenic pitting is thought to be a host mechanism of parasite 
removal. 
To examine the role of the spleen in clearing pRBC from circulation, splenectomized and 
sham-operated control mice were infected with fluorescently-labelled, PbG-infected blood, either in 
the presence or absence of artesunate treatment (Figure 3.4A). Surprisingly, in the absence of any 
drug treatment, surgical removal of the spleen did not alter the clearance of G0 pRBC from circulation 
(Figure 3.4B & C).  In contrast, in the presence of artesunate treatment, splenectomised mice removed 
G0 pRBC at a slower rate than sham-operated controls (Figure 3.4C). This suggested firstly that the 
spleen is not absolutely essential for pRBC, and raised the possibility that other organs might be able 
to compensate the absence of a spleen. In contrast, however, removal of drug affected parasites was 
impaired by splenectomy. This suggests that the spleen is required for removing drug-affected, and 
possibly dead parasites. Moreover, given the lack of effect on ring-stage parasites (Figure 3.4F), it 
appears that the spleen is likely capable of removing later-stage parasites more effectively that early 
rings. However, splenic removal of drug affected parasites did not alter control of Gen1 parasite 
growth (Figure 3.4 D & E), which suggested that artesunate-affected parasites removed by the spleen 
were likely dead or incapable of replication.  
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Figure 3.4 In the absence of artesunate treatment G0 pRBC clearance remains unaffected by 
splenectomy. (A) Splenectomized (Red) and sham control (blue) mice were infected  with fluorescent-
labelled PbG infected blood and immediately treated with 1000 µg artesunate  (dashed lines) or  
saline (solid lines). Tail bleed of recipient mice were done 1-97 h.p.i at different intervals and 
parasitaemia measured by flow cytometry. (B) Representative FACS plots showing G0 pRBC gates 
in vivo over time, (C) proportion of G0 pRBC remaining, and (D) FACS plots of Gen1+ pRBCs are 
shown for 25-75 h.p.i. and (E), Gen1+ pRBCs were graphed (F) The proportion of G0 pRBCs that 
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were remained in the circulation at ring-stage in vivo (n = 5 per group, error bars are SEM, p<0.01 
= **, p<0.001 = ***). Data representative of two independent experiments showing similar results. 
 
3.3.5 Phagocytes remove Gen0 pRBC but do not affect parasites progressing to Gen1. 
Phagocytes are important components of the host immune system. In malaria, phagocytes are 
thought to be essential for removing malaria parasites not only via receptor-mediated phagocytosis 
but also through the release of parasiticidal mediators [82, 172]. Clearance of pRBC or any parasitic 
material may also be achieved by circulating phagocytes (monocytes and polymorphonuclear 
leukocytes) [173]. Phagocytic clearance of parasites may also be enhanced following anti-malarial 
drug treatment, for example when splenic pitting of drug-damaged parasites from pRBC occurs [124].  
Contrary to these views, we observed that in general, artesunate and mefloquine did not accelerate 
clearance of the Gen0 parasites and there is a little effect of splenectomy in non-drug treated mice in 
the clearance of Gen0 pRBCs. While in vivo pitting rates have been estimated, and macrophages have 
been observed to phagocytose parasites, in vivo phagocytic clearance of pRBC has not been directly 
measured. This raises fundamental questions as to whether phagocytes such as Kuppfer cells (liver 
macrophages) contribute to clearance, either in the presence or in the absence of anti-malarial drugs. 
To examine a role of phagocytes in clearing pRBC in vivo, I conducted an experiment in which mouse 
phagocytic cells were depleted using clodronate-liposomes (Clod-Lip, Netherland) and Gen0 pRBC 
kinetics were assessed with/without artesunate treatment. Mice were intravenously injected with 
clodronate liposomes or control saline 3 days prior to transfusion with fluorescently-labelled, PbGFP 
(PbG)-infected blood and immediately treated with artesunate or control saline (Figure 3.5A). With 
the exception of the artesunate treated group, phagocytes depletion did not affect the total parasitemia 
in the first 25 hours (Figure 3.5B). However, depletion phagocytes resulted in Gen0 pRBC to remain 
in the circulation (Figure 3.5C & D) with little effect on the development of Gen1 pRBC (Figure 3.5 
E & F). This was unexpected in view of the common belief that phagocytes actively ingest free 
merozoites - a phenomenon necessary for transition of Gen0 to Gen1. Our data suggests that although 
phagocytes contributed to the removal of pRBC from the circulation, it also prevented merozoites 
invasion that is necessary for substantive reduction in net population growth. 
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Figure 3.5 Phagocytes remove pRBC from circulation with and without artesunate treatment. (A) 
Mice pretreated with clodronate liposomes (dashed lines, hollow circles, and hashed bars) or saline 
(solid lines, dots and bars), were injected with fluorescently labelled PbG infected blood and 
immediately treated with saline (black/grey) or 1000 µg artesunate (dark red). Tail bleed of recipient 
mice were done 1-73 h.p.i at different interval and parasitemia measured by flow cytometry. (B) Total 
parasitemia, (C) Representative FACS plots for Gen0 labelled pRBCs, (D) proportion of Gen0 pRBC 
remaining, (E) FACS plots of Gen1+ pRBCs are shown for 13-25 h.p.i., and   (F) Gen1+ pRBCs were 
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graphed. Dotted lines = detection threshold, (n = 5 per group). Data representative of three 
independent experiments showing similar results. Statistics: Mann-Whitney t-test, **P < 0.01. 
                                                                                                                                                                                                     
 
3.3.6 Acute host response impairs parasite maturation in Gen0 pRBC  
During blood-stage malaria, the number of parasites can increase exponentially by asexual 
replication, which occurs after the RBC invasion by merozoites. This includes a progression through 
ring, trophozoite and mature schizont stages before each pRBC produces tens of daughter merozoites 
for subsequent re-invasion of RBC. Each cycle is ~24, 48 or 72 hours in duration depending on the 
Plasmodium species. The total numbers of pRBCs increases by around 10-fold each cycle in a naïve 
individual infected with Plasmodium falciparum [174]. However, this rate of increase of pRBC can 
be reduced by a number of host humoral and cellular immune responses [175-177]. Whether and how 
other aspects of the host response to infection, such as host innate immune responses, may influence 
malaria parasite control remain unclear [178]. 
Animal models of malaria have revealed that during acute infection, specifically before the 
generation of an effective parasite-specific antibody response, the host is able to partially control 
parasite growth [135, 179, 180]. However, the precise mechanism(s) by which parasite numbers are 
reduced in vivo remains unknown. A number of potential hosts innate control mechanisms have been 
suggested, such as phagocytic removal of pRBC, either by the spleen or liver, which is considered as 
the primary mechanism for host control of parasite numbers [179]. However, only a few studies have 
attempted to directly measure host removal of pRBCs in vivo [180, 181]. 
Here, we compared the rate of removal of Gen0 pRBC from the circulation in acutely infected 
(with PbA-GFPneg pRBC) mice (compared to un-infected controls) after transfusing them with 
fluorescent-labelled Plasmodium berghei ANKA-GFP (PbG) donor pRBCs. Surprisingly, we 
observed that in acutely infected mice, Gen0 pRBC were not cleared faster than in un-infected controls 
(despite elevated systemic cytokine responses) (Figure 3.6B & C), rather Gen0 pRBC persisted longer 
in the circulation (Figure 3.6C). In addition, slower progression to Gen1 pRBC was observed (Figure 
3.6E). Flow cytometric assessment of life-stages using DNA/RNA dyes, Hoechst and Syto84, 
demonstrated surprisingly, that Gen0 pRBCs exhibited slower maturation rates in previously-infected 
mice (Figure 3.6F).  However, the mechanisms of slower maturation in acutely infected mice 
remained unclear. Subsequently, we investigated whether host responses were involved in impaired 
maturation. Rag1-/- mice which mount very weak systemic inflammatory responses during infection, 
including a weak production of TNF and IFNγ [135] were used. The data suggested that there was 
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little difference in the parasite clearance in naïve and infected rag1-/- mice (Figure 3.6C). Moreover, 
progression from Gen0 to Gen1 was substantially slowed in rag1
-/- infected mice (Figure 3.6E), either 
in 5-d or 12-d infected rag1-/- mice (Figure 3.6F). Further, the data suggest that host innate-immune 
response can prevent parasite replication as well enhanced parasite clearance through production pro-
inflammatory cytokines.  
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Figure 3.6 Acute infection impaired parasite development. (A) Different groups of mice were 
infected with CTFR-labelled PbG infected donor blood. Tail bleed of recipient mice were done 1 - 97 
h.p.i at different intervals and parasitaemia measured by flow cytometry. (B) Representative FACS 
plots for donor labelled RBC and (C) proportion of Gen0 pRBCs remaining for 1-25 h.p.i. (D) FACS 
plots of Gen1+ pRBCs are shown for 13-25 h.p.i. and (E), Gen1+ pRBCs were graphed (F) The 
proportion of G0 pRBC that were schizonts in vivo. (n = 5 per group, error bars are SEM, p<0.01 = 
**, p<0.001 = ***). Data representative of two independent experiments showing similar results.  
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3.4 Discussion 
In these experiments, we examined the role of phagocytes in controlling parasite numbers, 
both the presence and in the absence of drugs.  We observed a complex role of phagocytes that 
involved a clear capacity for removing a particular generation of pRBC, but no striking impact on 
total parasitemia. This may because of competing roles for phagocytes in both removal of pRBC and 
promoting parasite growth via pro-inflammatory responses or other unknown mechanisms. 
It has also observed that the effects of anti-malarial drug on the parasite growth occurred in a 
dose-dependent manner, where the high dose of artesunate and mefloquine (1000µg and 250 mg/kg 
respectively) completely suppressed parasite growth in the first 48 h after treatment, whereas parasite 
growth was evident in mice treated after 24 h of treatment with lower doses and in the lowest dose of 
Mefloquine and in control mice (saline treated). We could not, however, characterise the status and 
proportion of parasites that contributed to further replication. As other studies have noted, survival of 
a sub-population could potentially lead to the rapid emergence of drug resistance to artemisinin 
monotherapy [182], the clinical use of combined therapy improves the cure rate and delays the 
development of parasite resistance to artemisinin [183-185]. 
In the combination therapy study, it was observed that artesunate plus mefloquine combined 
treatment was more effective in the controlling total parasitemia compared to artesunate treatment 
alone. Our findings are consistent with the effectiveness of ACT in controlling parasites, which has 
been observed in an ACT ex vivo efficacy study [186].  Moreover, mefloquine delayed the parasite 
maturation process but did not completely inhibit parasite maturation, allowing limited progression 
to the next generation of parasites. 
Here, it was observed that artesunate treatment caused Gen0 pRBCs to remain longer in 
circulation, which consequently lowered the numbers of pRBCs below detection level in the next 
generation (Gen1+ pRBCs), by preventing parasite transition from one generation to the next. 
Therefore, it was interesting to study whether host factors were involved in this situation of parasite 
control; either by enhancing the removal of artesunate treated killed or damaged parasite or delaying 
parasite maturation. Previous ex vivo spleen perfusion studies suggested that the spleen more 
efficiently removes the mature trophozoites and schizonts stages parasites with an approximately 50% 
shorter half-life than the ring form [187]. In contrast, it has also observed that the depletion of 
phagocytes was associated with increased persistence of drug-affected young-stage parasites. This is 
consistent with the belief that artesunate-affected ring-stage parasites are usually removed actively 
from circulation via “pitting” [122, 126] - a mechanism in which the affected parasite is removed 
from the RBC and the cell is returned to the circulation, which is likely to involve phagocytic cells 
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[122, 126, 188]. Interestingly, our splenectomy experiments tend to suggest that the spleen is not 
essential for removing viable parasites from the bloodstream, as the removal of spleen did not alter 
the clearance of Gen0 pRBC. This is an important point because it tends to be assumed that the spleen 
clears pRBC from the bloodstream effectively. However, the splenectomy experiments should be 
interpreted with caution because compensatory mechanisms likely exist, such as liver macrophages 
taking up more parasites in splenectomised mice [189]. Nevertheless, we propose that the spleen is 
not a major organ for pRBC removal. It is, however, the main site for priming pathological immune 
response, which are not easily compensated for in splenectomise mice. Given that splenic T-cell 
responses actually promote parasite numbers in this model, the overriding effect of splenectomy is to 
block gen1 without having major effects on Gen0. The limitation of this study is that it could not 
explore possible roles of different polymorphonuclear cells in the observed reduced clearance of 
parasites by using clodronate liposomes that acts broadly on many phagocytic cells including 
macrophages, dendritic cells, and granulocytes [128, 190].  
Finally, we have shown that in acutely infected mice G0 pRBC persists longer in the 
circulation by delaying parasite maturation. Delayed parasite maturation was also observed in 
association with artesunate treatment, where parasites could not develop into schizonts. Other studies 
in P. falciparum also suggested that drug treatment was able to slow or halt (dormancy) the life-
cycles, which is thought to be a parasite stress response allowing parasites to survive treatment [155, 
182, 191, 192]. Therefore, it seems likely that delayed maturation is a parasite survival mechanism, 
which occurs in response to environmental stress, perhaps as a result of its efforts to mitigate damage 
caused by some form of stress, whether exerted by a drug or by the host environment. It thus appears 
that delayed maturation could be a parasite survival strategy, although the mechanism of delayed 
maturation remains unclear. However, in our experimental approach, transfusion of identical infected 
donor cells from a single donor mice into naïve and acutely infected mice enabled us to examine the 
ability of the host environmental factors to act on pre-infected cells and thereby influencing the 
parasite life-cycle development. Moreover, it is evident here that sensing of the environment by the 
parasite is a rapid response since the persistence of Gen0 pRBcs was evident after the first time point. 
In addition, we have identified a key role of host factors in this process. Parasite maturation was not 
delayed in rag1-/- mice, which lack both T and B cells and other abnormalities of lymphoid 
architecture. This does not imply that antigen-specific immunity is required for delayed maturation, 
as T and B cells are known to also contribute to the early innate immune response through the 
production of cytokines [193-195]. 
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 Moreover, in the PbANKA  model, a pathogenic immune response generate in the spleen 
depends on dendritic cells priming of pathogenic CD4+ and CD8+ T-cells. In particular, it is known 
that CD8+ T cells migrate to the brain where they cause fatal pathology via expression of molecules 
such as granzyme B [196]. It is also known that this CD8+ T cell response promotes parasite growth 
via as yet undefined mechanisms. Therefore, while the spleen might be regarded as the site for 
clearance of pRBC by host inflammatory response, it also is the site for a pathogenic pro-
inflammatory and T-cell response. Spleen thus plays a complex role in PbANKA infections, in that 
there may be a balanced inflammatory and host clearance mechanisms occurring in the same organ.  
In order to observe parasite life-stage development using our approach, we specifically chose 
to transfer semi-synchronous ring-stage Gen0 pRBCs, which facilitated us in examining the process 
of parasite maturation and development. Although we did not observe faster removal pRBCs from 
the circulation by the host, we could not entirely exclude the role of the spleen in the clearance of 
pRBC during infection; however, it was evident that slow maturation exerts a major impact on the 
overall parasite growth in acute infection [144]. Further studies are needed to identify the exact 
molecular mediators of delayed maturation. Importantly, we have shown that this experimental 
approach is a powerful tool for dissecting host-parasite interactions during blood-stage Plasmodium 
infection in vivo. 
Using the clearance /growth assay in mice has allowed measuring the clearance of parasite under a 
number of conditions including drugs, the presence of spleen, the role of phagocytes, and the 
influence of host pro-inflammatory responses. To definitively examine the role of phagocytes in 
removing pRBC, we had to focus on the effect of phagocytes on a defined population of pRBC, in 
this case Gen0. We observed the kinetics of loss of Gen0 pRBC in mice treated with clodronate 
liposomes to untreated mice, as well as repeating this comparison in mice treated with artesunate. We 
noted a profound reduction in the rate of loss of Gen0 in mice treated with clodronate. This indicates 
that phagocytes play an important role in clearing pRBC from mice. The effct of clodronate on Gen1, 
is complex because phagocytes not only clear pRBC, but also preserve the integrity of immune tissues 
such as the spleen.in the absence of phagocytes, T /B cells are not retained well in the spleen,and as 
a result pathogenic immune responses are abrogated. However, our experimental design did not allow 
examining whether or not phagocytes interfere with the maturation rates of parasites. We hypothesize 
that other mechanisms might play a role in supporting parasite growth, e.g. phagocytes in the spleen 
might facilitate rupture of schizonts as they pass through the organ, or pro-inflammatory responses 
might alter the micro-architecture of the spleen in some way to facilitate their rupture. These would 
be further explored in humans infected with Plasmodium by developing new techniques. 
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Chapter Four: 
Exploring mechanisms of antibody-mediated parasite control during 
blood-stage Plasmodium infection  
 4.1 Abstract 
Plasmodium-specific antibodies can play an important role in immunity to malaria, as 
exemplified by the fact that their passive transfer can control infection [197]. However, the exact in 
vivo mechanisms of action for these antibodies remain unclear. Using murine models of immunity to 
blood-stage malaria, P. yoelii 17XNL, and P. chabaudi chabaudi AS infection, I have studied the 
effect of parasite-specific antibodies in controlling malaria parasites in vivo. Data revealed that 
passive transfer of serum from immune animals did not lead to faster clearance of parasitized red 
blood cells (pRBCs), despite being effective at preventing parasite growth. Next, it was 
observed, via clodronate liposome treatment, that phagocytic cells played a partial role in the 
efficacy of antibody-mediated control. In contrast, cobra venom factor treatment suggested no 
role for C3/C5 complement factors. Finally, it was noted that parasite-specific IgG from these 
two mouse models bound poorly to the surface of pRBC in vivo and in vitro, and instead were 
capable of recognising parasite structures found in asexually replicative forms of the parasite, 
that we reason to be merozoites. Thus, in mouse models of humoral immunity to malaria, 
parasite-specific antibodies bind poorly to pRBC and consequently protect against infection by 
preventing parasite transition from one generation of pRBC to the next, most likely via 
phagocyte-dependent control of free merozoites.  
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4.2 Introduction 
Antibodies are an important component of acquired immunity against malaria, as 
demonstrated in the passive transfer of immune serum, firstly in rhesus monkey [101], and later in 
malaria-infected children which resulted in a reduction of parasite load and improved clinical status 
[102-104]. These findings provided the understanding that parasite-specific antibodies are able to 
effectively control parasite numbers in humans and in vivo animal models.  
In endemic populations, naturally-acquired immunity to malaria takes 10-15 years of exposure 
to develop, as individuals experience repeated exposures to malaria parasites [30].  Efforts have been 
made to identify potential antigenic targets of protective antibodies [105, 106]. The mechanism by 
which they control parasite numbers in vivo has also been reviewed [105, 107-109]. Protection against 
malaria likely depends on the functionalities of antibodies produced against parasite proteins exported 
to the surface of pRBC and/or to those expressed on the surface of merozoites [105], However, the 
mechanism by which antibodies protect against malaria remains unclear.  
A number of possible in vivo antibody-mediated mechanisms have been reported and revealed 
in elegant in vitro assays targeting Plasmodium proteins on pRBC. These include Growth Inhibition 
Assays (GIAs) [110, 111], which assess if antibodies can reduce parasite growth in the RBC over a 
few replication cycles; opsonic phagocytosis assays and antibody-dependent cellular inhibition 
(ADCI) assays [112-114], which assess whether antibodies facilitate uptake and/or inhibition by 
phagocytes; and complement-fixing and killing assays [115, 116], which assessed how well 
antibodies facilitate C1q deposition and complement-dependent direct killing. The correlation 
between the functional efficacy in GIAs and immunity to malaria remains unclear [117-120]; 
however, in recent years, methods to assess opsonic phagocytosis or C1q-fixation in vitro (mostly of 
merozoites), have demonstrated its correlation with protection against P. falciparum malaria 
symptoms and high-density parasitemia [114-116]. These reports suggested that antibody-mediated 
immunity to the blood-stage of infection can be mediated by their binding to merozoites, but requires 
the engagement of host factors including phagocytes and the complement system. More recently, it 
was also suggested that antibodies against the pRBC surface protein, PfEMP1, which drove opsonic 
phagocytosis in vitro, demonstrated partial protection against malaria and that these antibodies were 
acquired slightly earlier in life compared to merozoite-targeting antibodies [121]. Thus, the 
epidemiological data in humans supports the notion that multiple co-existing mechanisms acting 
against merozoites and pRBC may contribute to antibody-mediated pRBC control during blood-stage 
infection. However, few if any of these mechanisms have been convincingly observed in vivo.  
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 To explore in vivo mechanisms of action for protective antibodies acquired after blood-stage 
infection, I employed established models of blood-stage immunity in inbred C57BL/6J mice, and 
adapted the in vivo Clearance/Growth assay from Chapter 3, for use with Py17XNL and PcAS 
parasites [134, 198, 199]. This allowed tracking of a cohort of labeled pRBC and direct estimation of 
how antibodies controlled infection with homologous parasites. Non-lethal Py17XNL and PcAS 
infections were chosen due to their self-resolving nature and their well-documented production of 
parasite-specific antibodies, which are known for mediating immunity to re-challenge [200-202].  
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4.3 Results 
4.3.1 Assessing Py17XNL model and Clearance /Growth assay  
Prior to the exploration of in vivo mechanisms of action of antibodies, it was important to 
assess whether the use of immune serum and our Clearance/Growth assay was indeed effective to 
study the mechanisms of antibody function in vivo. A number of parameters such as the amount of 
immune serum and the antibody exposure time required to exert the optimal functional impact were 
optimised before investigating the mechanistic aspects of antibody action using our laboratory’s in 
vivo Clearance/Growth assay. 
4.3.1.1 Immune and non-immune murine serum was generated using non-lethal P.yoelii 
17XNL  
To study the mechanisms of antibody-mediated parasite control in vivo, we opted to use 
immune serum from inbred C57BL/6J mice that had resolved a blood-stage P. yoelii 17XNL infection 
or control non-immune serum from un-infected age-matched mice. Py17XNL expresses parasite-
derived proteins on the surface of both pRBC and merozoites in a manner similar to human 
Plasmodium species [203-205]. It is a model characterised by robust humoral immunity, and the 
development of parasite-specific serum IgG and IgM. Previous data from our group and others have 
identified that Py17XNL-specific IgG and IgM was detectable by 14 d.p.i., that parasitemia was 
largely resolved by 30 d.p.i., and that peak parasite-specific IgG levels occurred at around 60-70 d.p.i. 
[206]. Thus, C57BL/6J mice were intravenously infected with 1x104 Py17XNL-infected pRBCs, 
infection was confirmed on day 12 p.i., and resolution of infection confirmed on day 30 p.i. (Figure 
4.1A). Mice were then monitored around day 60-70 p.i., to ensure that Py17XNL-specific IgG had 
been generated (Figure 4.1B). Serum containing parasite-specific IgG (and age-matched non-immune 
serum) was collected and stored for future experiments.  
 
 
Figure 4.1 Generation of Py17XNL-immune serum using the self-resolving non-lethal Py17XNL 
rodent model. (A) Immune mice were generated following blood-stage infection with P. yoelli 17XNL 
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(Py17XNL). Infection was confirmed 12 d.p.i., and (B) Py17XNL-specific IgG was measured 60-70 
d.p.i in immune (blue) and age-matched non-immune (red) mice (n=5-30/group); data representative 
of more than five independent experiments, each with similar results.  
 
4.3.1.2 Immune serum restricts parasite growth during Py17XNL infection 
After generation of immune and control non-immune serum from mice that had resolved  
primary Py17XNL infection and confirmation of the presence of parasite-specific IgG (Figure 4.1B), 
I next sought to determine if these antibodies could function in vivo to control infection, similar to 
the manner in which passive transfer of IgG was shown to protect malaria patients.  This meant 
determining whether immune serum was able to control parasitemia when therapeutically 
administrated to mice infected with homologous parasites (Figure 4.2). At day 3 p.i. when parasitemia 
was ~0.05%, infected mice were transfused with a single dose (200µl) of immune serum, or non-
immune control serum. Five out of 6 mice receiving immune serum partially controlled parasitemia 
over the subsequent 36 hours, compared to non-immune serum recipients (Figure 4.2).  Interestingly, 
the mouse with the highest starting parasitemia (~0.1%) showed no evidence of parasitemia control 
when administered immune serum, suggesting that parasite load might influence the efficacy of 
immune serum treatment. Nevertheless, these data confirmed that immune serum, which contained 
parasite-specific IgG, was protective in vivo. 
 
Figure 4.2 Efficacy of immune serum in restricting parasite growth in ongoing Py17XNL-
infection. Total parasitemia of individual Py17XNL-infected mice therapeutically treated at 3 d.p.i. 
with a single dose of Py17XNL-immune (blue) or non-immune (red) control serum (n=6 per group) 
and tracked for 36 hours thereafter; experiment conducted once. 
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4.3.1.3 Assessing in vivo mechanisms of action for Py17XNL-specific immune serum 
Having confirmed the in vivo protective capacity of Py17XNL-specific immune serum, it was 
next hypothesized that protection was mediated by accelerating the host-mediated removal of pRBC. 
To test this, I examined immune-serum mediated control of parasites using a modified version of our 
laboratory’s in vivo Clearance/Growth assay. In Chapter 3 this assay was used to examine the 
dynamics of P. berghei ANKA parasites. Here, I employed the same labeling techniques with 
Py17XNL pRBC. Non-immune mice were administered immune serum, non-immune serum, or no 
serum intravenously 2 hours prior to infection with fluorescently-labelled (with CellTrace Far Red, 
CTFR) pRBCs from Py17XNL-infected passage mice. Parasitemia was monitored in recipient mice 
from 1-73h post infection by flow cytometry. Firstly, the data suggest that mice receiving immune 
serum exhibited significant control of parasitemia over the 3-day period, compared to mice treated 
either with non-immune serum or no serum (Figure 4.3A and B). Interestingly, there appeared to be 
no difference in parasitemia kinetics between non-immune serum recipients and those not receiving 
any serum, which suggested that there was little bystander/non-specific protection afforded by the 
administration of non-immune serum.  Next, we made use of CTFR-labelling to define the first 
generation of transferred pRBC that were CTFR+ as Gen0, and subsequent CTFR- generations as 
Gen1+ pRBC. It was noted that immune serum recipients, efficiently impaired the transition of 
parasites from Gen0 to Gen1+ (Figure 4.3B), compared to non-immune recipients. Moreover, at earlier 
timepoints, most notably at 19h post-infection, Gen0 parasites, though lower in number than at 1h, 
were present at the same frequency regardless of immune serum transfer (Figure 4.3C).  Although 
this time point was not ideal for assessing removal of Gen0, it was clear that immune serum was 
highly efficient at preventing parasites in Gen0 pRBC from progressing to subsequent generations of 
pRBC. Further detailed assessment of earlier time points within the first 24 hours was required to 
examine pRBC clearance. 
 
Figure 4.3 Control of parasite growth without accelerated parasite removal. (A) Total parasitaemia, 
(B) growth of parasites (G1+ parasites population) in recipient RBC; and (C) reduction in the 
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proportion of donor pRBCs (G0 parasites population), called clearance; in WT mice pre-treated with 
150 µl immune serum (blue) and non-immune serum (red) and no serum (black, n=5 per group) two 
hours before infection with fluorescently labelled Py17XNL infected blood (i.e., donor G0 parasites 
population). Error bars represent SEM, p<0.01 = **. Data representative of two independent 
experiments showing similar results. 
 
4.3.1.4 Lack of Py17XNL-specific immune serum dose reponse in clearance of Gen0 pRBC 
 Thus far, arbitrary volumes of serum (ranging from 100-200µl) had been used to determine 
in vivo efficacy of immune serum in controlling parasitemia and parasite growth. In addition, frequent 
sampling of Gen0 pRBC had not been undertaken to test our hypothesis that immune serum 
accelerated host removal of pRBC from circulation.  Therefore, to identify an appropriate dose of 
immune serum to be used in future experiments, and to study Gen0 pRBC clearance, a range of serum 
doses (5, 20, 100 and 400µl of immune and 400µl of non-immune serum) were passively transferred 
2h prior to infection with CTFR-labelled Py17XNL-infected pRBC. Detailed flow cytometric 
examination of Gen0 and Gen1+ pRBC was conducted at 1, 6, 12, 18, 24, 48, 72 and 96 hours post-
infection.  It was striking, that while Gen0 pRBC were lost from circulation in the absence of immune 
serum, likely via the normal process of maturation and RBC rupture, the rate of loss of Gen0 pRBC 
was not accelerated by immune serum (Figure 4.4A). The data suggest that the animals immune 
system was adequate in removing the Go parasite population without requiring additional IgG. 
Importantly, however, immune serum when administered at the higher volumes of 400µl and to a 
lesser extent 100µl was highly effective at preventing progression to Gen1 pRBC (Figure 4.4B). These 
data firstly showed that doses of immune serum above 100µl were required to control parasite growth 
in our models. Due to logistical issues of using high volumes of immune serum, it was decided that 
200µl volumes (rather than 400µl) would ensure robust protection without having to generate 
excessively large batches of immune serum from Py17XNL-infected mice. Most importantly, 
detailed assessment of Gen0 pRBC revealed that immune serum did not control parasite numbers by 
accelerating the rate of pRBC clearance from circulation.  Instead, the data indicated that immune 
serum likely acted by preventing parasite transition from one generation pRBC to next. However, 
antibody in immune serum could possibly bind to the intra-erythocytic parasite to inhibit parasite 
development; but, we did not explore this in our study. 
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Figure 4.4 No dose-response in the clearance rate of pRBCs from circulation. (A) The graph shows 
reduction in the proportion of pRBCs (Gen0), called clearance; and (B) growth of parasites (G1+ 
parasites population) in recipient RBCs after rupturing from G0 parasites in WT mice (n=3) pre-
treated with 400, 100, 20 and 5µl of immune serum and 400µl non-immune serum at -2hrs to infection 
with fluorescently labelled Py17XNL infected blood (i.e., donor G0 parasites population). Error bars 
represent SEM, p<0.01 = **. Experiment conducted once. 
 
 
4.3.1.5 Modification of the immune serum passive transfer protocol  
Considering the reality of managing the experiment, it was essential to explore whether 
transferring serum into mice one day (24h) prior to infection was effective as 2h prior. In order to 
determine this, intravenous transfer of serum into mice was performed 2h and 24h prior to infection 
with fluorescently labeled pRBCs from Py17XNL infected passage mice. Tail bleeds of recipient 
mice were done at time intervals of 1-73h post-infection, and parasitemia monitored by flow 
cytometry. Data suggested that administration of non-immune serum to the recipient mice very close 
to the time of infection with pRBCs produced a similar, non-specific protection in the next generation 
of pRBCs (G1+), which was not observed in the earlier two experiments. In an effort to simplify the 
implementation of the experiments, we felt it prudent going forward to administer serum 24 hours 
prior to parasite challenge with donor pRBCs (Figure 4.5) though the experiment done once. 
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Figure 4.5 Administration of non-immune serum 2h prior to parasite challenge produces non-
specific protection in Gen1 pRBCs. Mice (n=5/group) were intravenously administered 200μl of 
Py17XNL immune serum (blue), or control non-immune serum (red) 2h (dotted lines) and 24h (solid 
lines) prior to receiving CTFR+ Gen0
 pRBC containing Py17XNL. Gen1+ pRBC analysed at time 
points indicated. Experiment conducted once.  
 
4.3.1.6 Cellular and humoral immunity do not increase parasite clearance in vivo 
 Although transferred antibodies inhibited parasite replication in naïve mice, it remained 
possible that additional immune mechanisms might operate in an intact immune mouse to accelerate 
Gen0 clearance. To explore this, immune mice that had resolved a primary Py17XNL infection were 
intravenously injected with CTFR+ pRBC (Figure 4.6A). As with passive antibody transfer, no 
changes were observed in Gen0 pRBC removal compared to age-matched naïve controls (Figure 
4.6B). In contrast, the emergence of Gen1 pRBC was blocked in immune mice compared to naïve 
age-matched controls (Figure 4.6C), with PMR (the average number of Gen1 pRBC generated at 25h 
from each transferred Gen0 pRBC at 1h) substantially reduced from 17.3±7.7 in non-immune mice to 
0.78±0.29 in immune mice. Together the data suggest that infection-induced, protective antibodies 
against Py17XNL parasites do not alter the rate of removal of pRBC in vivo. Instead, this data further 
confirms that these antibodies obstructed the progeny of pRBC from generating subsequent 
generations of pRBC. 
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Figure 4.6 Combined cellular and humoral immunity do not accelerate pRBC clearance. (A) 
Schematic showing that Py17XNL-immune (blue) and non-immune (red) mice (n=5/group) were 
challenged with CTFR+ Py17XNL-infected pRBC, with peripheral RBC monitored at time points 
indicated for: (B) loss of Gen0 (CTFR
+) pRBC over the first 25 hours, and (C) emergence over 3 days 
of Gen1+ (CTFR
-) pRBC, with zoomed-in box showing the first 25 hours in more detail. Data 
representative of two independent experiments showing similar results.  
 
4.3.2 Exploring the mechanisms of antibody-mediated parasite control 
A number of recent studies are in line with my observation that infection-induced antibodies 
were efficient at preventing Py17XNL parasite progression from one generation of pRBC to the next, 
without acceleration of parasite removal in the first 25h of p.i. Specifically, it has been suggested that 
antibody-mediated immunity to blood-stage infection can be effected by binding to merozoites, but 
with a necessary engagement of host factors including phagocytes and certain aspects of the 
complement system [114-116]. More recently, it was also suggested that antibodies against the pRBC 
surface protein, PfEMP1, which drove opsonic phagocytosis in vitro, afforded partial protection 
against malaria, and that these antibodies were acquired slightly earlier in life than merozoite-
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targeting antibodies [121]. Thus, the epidemiological data in humans supports the concept that 
multiple co-existing mechanisms acting against merozoites and pRBC can contribute to antibody-
mediated pRBC control during blood-stage infection. However, few if any of these mechanisms have 
been convincingly observed in vivo. Therefore, it was hypothesised that some of the antibodies 
elicited by Py17XNL infection would bind to pRBC and accelerate their clearance by the host.  
 
4.3.2.1 Infection-induced, Py17XNL-specific antibodies do not accelerate pRBC clearance, but 
prevent parasites progressing to the next generation of RBC 
After determining that passively transferred immune serum generated in inbred C57BL/6J 
mice against Py17XNL infection was effective in controlling parasitemia during challenge with 
CTRF labeled pRBCs,  I next made use of the CTFR-labelling on pRBC to specifically study the 
progression from the initial generation (Gen0) of pRBC to the next generation (Gen1+) over the first 
25 hours post-challenge. The experiment was carried out as previously detailed. Briefly, after 
collection of cardiac blood from Py17XNL-infected passage mice (typically exhibiting an age 
structure of 70% ring-stages), the blood was fluorescently labelled with CellTrace™ Far Red (CTFR) 
and transferred as the first generation, termed Gen0 (including un-infected, CTFR-labelled RBC) into 
mice that had received Py17XNL-immune serum or non-immune control serum 24 hours earlier 
(Figure 4.7A). Here, a combination of Hoechst 33342 and Syto™ 84 nucleic acid dyes was used to 
identify parasite life-cycle stages of Gen0 pRBC over the first 25 hours (Figure 4.7B). 
As earlier, the data suggested that the loss of Gen0 pRBC was equivalent between immune 
and non-immune serum recipients (Figure 4.7C), and allows the inference that pRBC clearance rates 
remained unaffected by passive transfer of protective immune serum. Similarly, Gen0 parasite 
maturation occurred equivalently in immune and non-immune serum recipients over the 25-hour 
observation period (Figure 4.8).  Next, while the rapid appearance of Gen1+ pRBC was observed in 
non-immune serum recipients, the immune serum substantially blocked the emergence of Gen1+ 
pRBC (Figure 4.7D). The PMR in mice that received control serum was 11.5±0.8, which was reduced 
to 3.7±0.1 in mice that received immune serum. Together, these data demonstrated that parasite-
specific antibodies are able to control Py17XNL infection. This does not appear to be due to the 
accelerated removal of pRBC or impaired parasite maturation, but due to blocking the progeny of 
Gen0 pRBC from establishing subsequent generations of pRBC. 
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Figure 4.7 Infection-induced antibodies control Py17XNL parasite growth, not by accelerating 
pRBC clearance, but by blocking subsequent generations of pRBC. (A) Schematic diagram showing 
mice (n=5/group) injected with serum from Py17XNL-immune (blue) or non-immune (red) mice 24h 
prior to challenge with CTFR-labelled Py17XNL-infected pRBCs, and the timing of tracking the 
infection progression by flow cytometry. (B) FACS gating strategy employed to analyze Gen0 and 
Gen1+ pRBC: forward scatter area and height (FSC-A and FSC-H) used to identify single cells, and 
side scatter area (SSC-A)/FSC-A used to identify RBCs. CTFR+ pRBCs were the initial generation 
(Gen0), while Hoechst 33342/Syto 84 co-staining identified pRBCs and their life stages. (C) 
Representative FACS plots for time-course analysis of loss of Gen0 (CTFR
+) pRBC with numbers 
showing % of CTFR+ RBC containing parasites and the summary graph as a % of total RBC in 
recipient mice. (D) Representative FACS plots for time-course analysis of Gen1+ (CTFR
-) pRBC, and 
summary graph showing emergence of Gen1+ pRBCs over time. Data are representative of six 
independent experiments, each showing similar results.  
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Figure 4.8 In vivo maturation of Gen0 Py17XNL-infected pRBC is unaffected by exposure to 
Py17XNL-immune serum. Representative FACS plots gated on Gen0 (CTFR
+) RBC in mice 
(n=5/group) at indicated time points after transfer into mice that had received either Py17XNL-
immune or non-immune control serum 24h previously, showing parasite life-stages based on Hoechst 
and Syto 84 profiles. Graphs show percentage of Gen0 pRBC in each life stage. Data are 
representative of >5 independent experiments, each showing similar results. 
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4.3.2.2 Py17XNL-specific antibodies require phagocytic cells for optimal function in vivo 
Antibodies may provide protection against malaria in different ways, including inhibition of 
the blood-stage replication preventing high-density parasitemia. A number of possible mechanisms 
have been proposed based on in vitro assays. Protection against P. falciparum infection may be 
mediated by binding of antibody to the merozoites thereby limiting the number of parasites, a process 
that involves host factors including the complement systems and phagocytes [207, 208]. A recent 
study has reported that anti-malarial antibodies in association with complement factor C1q-fixation 
inhibit invasion of erythocytes by merozoites, and facilitate complement deposition and lysis of 
merozotes [209]. Antibodies are also involved in the phagocytosis of P. falciparum merozoites, and 
in the activation of monocytes to producepro-inflammatory cytokines [114]. Phagocytic cells 
constitute an effective mechanism for reducing parasitemia. In this process, antibody acts as an 
opsonin and binds to infected erythrocytes (IE) or merozoites for phagocytosis. However, the exact 
in vivo mechanism(s) remains unknown. Thus, we wanted to determine the mechanisms involved in 
antibody-mediated parasite control. 
Before investigating whether antibody control of parasite growth in vivo requires help from 
host factors such as phagocytic cells and complement or both, a control experiment was performed 
to understand the role of phagocytic cells in controlling parasites in vivo. Mouse phagocytic cells 
were depleted using a crude Clodronate-liposome (Clod-Lip, Netherland) treatment 3 days before 
administering donor pRBCs (Figure 4.9A). In the event of clearance by phagocytic cells following 
artesunate treatment, it might be expected that clodronate depletion could help parasites persist even 
longer in the circulation. In the event of no clearance by macrophages, it might be expected there 
would be exactly the same clearance in the artesunate-treated group with and without clodronate. 
Indeed, results of this experiment suggested an important role of phagocytic cells since the removal 
of the phagocytic cells resulted in the persistence of pRBCs in the circulation during the first 24 hours 
of infection compared to the control group (Figure 4.9B). However, there was no significant 
difference in parasite growth in the next cycle between the groups (Figure 4.9C). 
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Figure 4.9 Phagocytes remove pRBC from circulation with and without artesunate treatment. (A) 
Schematic diagram showing that mice treated with 200 µl of clodronate liposomes (dashed lines in 
B and C) 3 days prior to infection with fluorescently labelled Py17XNL-infected blood and 
immediately treated with saline (grey) or 1000 µg artesunate (red). (B) The graph shows reductions 
in the proportion of donor pRBCs (G0 parasite population), called clearance and (C) growth of 
parasites (G1+ parasite population) in recipient RBCs after rupturing from G0 parasites. Error bars 
represent SEM, p<0.01 = **. Data representative of two independent experiments showing similar 
resuts.   
 
Next, the role of phagocytes in the mechanism of anti-malarial antibody protection was 
assessed in vivo by pre-treating mice with clodronate liposomes before treatment with Py17XNL-
immune serum (or control non-immune serum). Afterward, CTFR+ labeled pRBC (Gen0) were 
transferred and tracked as below (Figure 4.10A). Over the first 25 hours, phagocyte depletion slightly 
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reduced the rate of clearance of Gen0 pRBC in both control and immune-serum treated mice (Figure 
4.10B). When the effects of immune serum in clodronate-treated mice were examined, it was 
observed that clodronate treatment had reduced the protective effect of immune serum.  That is, in 
phagocyte-intact mice, immune serum reduced PMR by 61.7% (range: 50-70) compared to control 
antibody-treated mice (Figure 4.10C). However, in phagocyte-depleted mice, immune serum reduced 
PMR by only 31.7% (range: 25-40) (P<0.0096, two-way ANOVA, significant interaction between 
serum administration and clodronate treatment, 5 mice/group, three independent experiments). Thus 
Py17XNL-immune serum was ~50% less effective in the absence of phagocytes over the first 25 
hours. Nevertheless, at days 2 and 3 post-transfer, immune serum had limited the emergence of later 
generations (Gen1+) of pRBC in both phagocyte-depleted and intact mice (Figure 4.10C). Therefore, 
Py17XNL-specific antibodies co-operated with phagocytic cells to optimally restrict parasites 
transitioning from Gen0 to Gen1 pRBC. 
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Figure 4.10 Py17XNL-specific antibodies require phagocytic cells for optimal in vivo function. (A) 
Schematic showing 4 groups of mice (n=5/group) treated with clodronate liposomes (dashed lines) 
or left untreated (solid lines), and then given immune (blue) or non-immune (red) control serum prior 
to infection with CTFR+ Py17XNL-infected pRBC, with peripheral blood assessed at different time 
points for: (B) loss of Gen0 (CTFR
+) pRBC and (C) emergence of Gen1+ (CTFR
-) pRBC in phagocyte 
replete (left), or clodronate liposome-treated (right) mice with the first 25h in detail. Percentages 
indicate the reduction in PMR elicited by immune serum compared to non-immune control serum. 
Data representative of three independent experiments showing similar results. 
 
4.3.2.3 Py17XNL-specific antibodies do not require complement mediated direct killing for 
optimal function in vivo  
Next, phagocyte-independent mechanisms that antibodies might employ to prevent parasites 
transitioning from Gen0 to Gen1 were examined. Previous studies had reported two antibody-
mediated, phagocyte-independent mechanisms: complement-dependent merozoite invasion blockade 
that requires C1q-deposition, and complement-mediated direct lysis of merozoites via the formation 
of membrane attack complexes (MAC). To test for the importance of MAC formation in the 
protective efficacy of Py17XNL-immune serum, we depleted mice of complement protein C3, using 
non-toxic cobra venom factor (CVF). Importantly, CVF-treatment does not target C1q, the upstream 
component of the complement cascade that can complex with antibodies to block merozoite invasion. 
CVF treatment leads to complement depletion by activating the alternative pathway of C3 activation 
[210]. To explore the role of complement in antibody-mediated parasite control, complement in WT 
mice was depleted by ~75-90% by continuous administration of 10 µg/mouse CVF (Quidel, San 
Diego, California) or saline control from days – 1 to + 3. Then Py17XNL-immune serum or non-
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immune serum was transferred (day -1), and on the following day (day 0) CTFR+ labeled pRBCs 
were administered and tracked (Figure 4.11A). Firstly, it was confirmed that CVF treatment had 
substantially depleted C3 levels in the serum by measuring C3 levels every 24 hours post infection in 
CVF treated and saline-treated control mice (Figure 4.11B). As expected, the loss of Gen0 pRBC was 
equivalent amongst all groups (Figure 4.11C). Finally, PMR reduction elicited by Py17XNL-immune 
serum (compared to non-immune serum) in mice either replete or CVF-treated were compared 
(Figure 4.11D). It was found that Py17XNL-immune serum effectively controlled PMR in both CVF-
treated mice and saline controls (P>0.12, two-way ANOVA interaction between immune serum 
administration and CVF treatment, 5 mice per group, 2 independent experiments). Therefore our data 
could not define any clear role of antibody-dependent, complement membrane attack complex 
(MAC)-mediated direct lysis in the process of protection conferred by Py17XNL-immune serum 
antibodies. Taken together, our data suggests that infection-induced Py17XNL-specific protective 
antibodies co-operated with phagocytes, but did not engage complement-mediated direct killing to 
block parasite transition from one generation of RBC to another. However, we did not assess 
complement component C1q-mediated blocking of invasion of erythrocytes by merozoites, and we 
thus consider a possible role of complement. 
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Figure 4.11 Py17XNL-specific antibodies do not require complement-mediated direct killing for in 
vivo function. (A) Schematic showing 4 groups of mice (n=5/group) treated with immune (blue) or 
non-immune (red) control serum, and cobra venom factor (CVF, green) or control saline as indicated 
by green arrows, and challenged with CTFR+ Py17XNL-infected pRBC. (B) Serum C3 levels assessed 
at various times post-challenge. (C) Loss of Gen0 (CTFR
+) pRBC and (D) emergence of Gen1+ 
(CTFR-) pRBC in C3-replete, or CVF-treated mice with detail of the first 25h. Data represents two 
independent experiments showing similar results.  
 
 
4.3.2.4 Py17XNL-specific IgG binds poorly to intact pRBC, but strongly to permeabilised 
schizonts harbouring merozoites  
Next, the life-cycle stage specificity of Py17XNL-specific antibodies was examined. Given 
that immune serum blocked parasite transition from one RBC to another, rather than accelerating 
pRBC clearance, we hypothesized that these antibodies might bind poorly to the pRBC surface but 
strongly to merozoite forms. To test whether immune serum antibodies bound to the surface of pRBC 
in vivo, Py17XNL-immune serum or non-immune control serum were passively transferred as before, 
and CTFR+ pRBC transferred on the following day (Figure 4.12A). Then, Gen0 pRBC was stained 
for cell-surface mouse IgG ex vivo after 1 or 4 hours (Figure 4.12B). As a positive control for mouse 
IgG-deposition on RBC, some samples were also incubated in vitro with a mouse monoclonal IgG 
(clone 34-3C) specific for murine RBC (Figure 4.12B). These analyses demonstrated firstly that this 
assay was capable of detecting mouse IgG bound to the surface of CTFR+ RBC (Figure 4.12B). 
Secondly, after 1 hour of in vivo exposure to immune serum, less than 10% of pRBC had bound 
mouse IgG to levels above background (Figure 4.12B), a proportion that did not increase after another 
3 hours of in vivo exposure (Figure 4.12B), or even following incubation with higher concentrations 
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of immune serum in vitro (Figure 4.13A). These data support the hypothesis that, compared to the 
34-3C a positive control, Py17XNL-specific IgG bound only weakly to the surface of pRBC in vivo 
(Figure 4.12B). Noted that, the reduced antibody activity could be due to the variant nature of the 
variant surface antigens of pRBC. 34-3C, a RBC marker is much more abundant than variant surface 
antigens of pRBC, however, we have used 34-3C as a positive control in our experiments to assess 
the binding activity. 
Next, to test whether parasite-specific IgG, present in immune serum, could potentially bind 
merozoites, parasites inside pRBC were exposed directly to immune serum in vitro, by RBC fixation 
and permeabilisation (Figure 4.13B). Interestingly, it was observed that although fixation and 
permeabilisation lysed all un-infected RBC and perhaps early-ring stage pRBC, as expected (Figure 
4.13B compared to 4.13A), later-stage pRBC remained intact, permitting immune-staining and 
conducting flow cytometry (Figure 4.13B). In stark contrast to pRBC-surface IgG deposition, where 
the majority of pRBC did not bind IgG from immune serum (Figure 4.12B), it observed that ~90% 
of parasites within the intact, permeabilised pRBCs strongly bound IgG from immune serum, 
compared to <5% with control serum (Figure 4.13B). Additionally, pRBCs with the highest DNA 
content, indicative of progression through schizogony and generation of merozoites, exhibited the 
strongest Py17XNL-specific IgG staining (Figure 4.13C). These data were consistent with IgG in 
immune serum displaying stronger specificity for merozoites than for pRBC.  Taken together, this in 
vivo and in vitro data supported the hypothesis that infection-acquired Py17XNL-specific IgG 
antibodies bind poorly to the surface of pRBC. However, this was not due to a lack of recognition of 
parasite antigens, since antibodies did bind to permeabilised pRBC (increasing binding with parasite 
maturation). These data suggest a specificity for merozoite forms, consistent with effects in blocking 
parasite replication. Moreover, keep in mind that the cells were fixed only after the binding assay was 
performed, it seems unlikely that fixation masked the presence of parasite antigen on the surface. 
Given that fixing was required for intracellular staining, it is possible though unlikely, that this 
process revealed antigens otherwise hidden on the cell surface. Further microscopical analysis of 
staining may be required in future experiments. 
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Figure 4.12 Py17XNL-specific IgG binds weakly to intact pRBCs. (A) Schematic showing  mice 
(n=5/group) injected with immune (blue) or non-immune (red) control serum 24h prior to infection 
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with CTFR+ Py17XNL-infected pRBCs, with surface deposition of IgG on pRBC assessed 1h and 4h 
afterwards. (B) Representative FACS plots showing detection of in vivo-deposited mouse IgG on the 
surface of CTFR+ RBC (after 1h & 4h in vivo exposure), with positive controls stained in vitro with 
RBC-specific mouse IgG (34-3C). Data represents two independent experiments showing similar 
results. Statistics: Mann-Whitney-test, **p<0.0. 
 
 
 
Figure 4.13 Py17XNL-specific IgG exhibits strong binding specificity for structures in schizonts. 
(A-B) Detection of in vitro deposited IgG from immune (blue) or non-immune (red) control serum 
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either: (A) on the surface of RBC from Py17XNL-infected mice, or (B) inside RBC from Py17XNL-
infected mice after fixation/ permeabilisation. Graphs show proportion of pRBCs bound. (C) 
Representative histogram showing gating for identifying Py17XNL pRBC containing different 
numbers of merozoites using Hoechst. Graph shows variations in the geometric mean fluorescence 
intensity of in vitro IgG deposition inside fixed and permeabilised pRBC according to DNA content, 
when incubated with immune or non-immune control serum (assessed in triplicate). Two-tailed 
Students T-test, p=0.0004. Data in (A-C) represents four independent experiments each with similar 
results.  
 
4.3.2.5 P. chabaudi chabaudi AS infection induced antibodies also protect by blocking the next 
generation of pRBC rather than accelerating pRBC clearance  
Having explored the function of antibodies elicited during the primary blood-stage Py17XNL 
infection to protect against homologous re-challenge, next it was sought to determine whether such 
mechanisms might also act in a second common model of antibody-mediated immunity to malaria - 
P. chabaudi chabaudi AS infection of mice.  Here, immune serum was harvested from PcAS-infected 
wild-type C57BL/6J mice at 40 d.p.i. because earlier time course analysis had revealed this to be the 
peak period of parasite-specific IgG in this model [211]. First, it was confirmed that PcAS-specific 
IgG was indeed present in immune serum preparations (Figure 4.14A). Next, the CTFR-labelling 
approach was used as above, using PcAS-infected CTFR+ pRBC, transferred into mice that also 
received PcAS-immune serum or age-matched control serum 24 hours earlier (Figure 4.14B).  Firstly, 
it was observed that the loss of Gen0 pRBC was again not influenced by PcAS-immune serum (Figure 
4.14C) although the emergence of Gen1+ pRBC was clearly impaired (Figure 4.14D) with PMR 
reductions of ~50% for immune serum compared to control serum. Consistent with no effect on pRBC 
clearance, and strong effects on Gen0 to Gen1 transition, it also observed that PcAS-specific IgG did 
not bind well to the surface of pRBC in vitro (Figure 4.15A), but was capable of binding to 
intracellular parasite antigens inside late-stage, permeabilised pRBC (Figure 4.15B). This data using 
a second model of antibody-dependent immunity exhibits striking similarities to the earlier 
observations with Py17XNL. Thus, in two independent models, infection-induced antibodies bound 
poorly to the surface of pRBC but provided robust protection, not by clearing pRBC but by blocking 
pRBCs from successfully generating daughter pRBCs. 
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Figure 4.14 P. chabaudi chabaudi AS infection induced antibodies also protect by blocking 
transition of parasites between RBC, not by accelerating pRBC clearance.  (A) Assessment of PcAS-
specific total IgG in diluted sera from infected or age-matched naïve mice (n=10/group), taken at 
day 40 p.i. with PcAS. (B-D) Mice (n=5/group) were injected with PcAS-immune serum (blue) or 
non-immune (red) control serum 24h prior to challenge with CTFR+ PcAS-infected pRBCs, with 
peripheral blood monitored at times indicated for: (C) loss of Gen0 (CTFR+) pRBC over the first 
25h, and (D) emergence of Gen1+ pRBC over 73h, with the zoomed-in box showing the first 25h in 
more detail. Data representative of two independent experiments showing similar results.  
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Figure 4.15 P. chabaudi chabaudi AS –specific antibody binds weakly to intact pRBC, yet exhibits 
substantial specificity for structures in schizonts. Assessment of in vitro deposition of mouse IgG 
from PcAS-immune (blue) or non-immune (red) control serum performed in triplicate, either: (A) on 
the surface of RBC from PcAS-infected mice, or (B) inside RBC from PcAS-infected mice after 
fixation/permeabilisation. Graph shows percentage of pRBC binding to mouse IgG after 
fixation/permeabilisation. (C) Representative histogram shows gating for identifying PcAS-infected 
pRBC containing different amounts of parasite DNA using Hoechst. Graph shows variation in 
geometric mean fluorescence intensity of in vitro IgG deposition inside fixed and permeabilised pRBC 
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according to DNA content. Data are representative of two independent experiments each with similar 
results. 
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4.4 Discussion 
Antibodies play a key role in controlling parasite numbers during blood-stage malaria. 
However, the in vivo mechanisms of antibody-mediated parasite control are not well known.  
Several mechanisms have been proposed to explain how Plasmodium-specific antibodies may 
prevent or ameliorate malaria. Broadly speaking, these include three mechanisms: (i) antibodies act 
mostly alone without the need for other host processes; (ii) antibodies serve as triggers for phagocyte-
dependent processes (opsonic phagocytosis and antibody-dependent cellular inhibition (ADCI)); or 
(iii) antibodies activate complement-mediated direct killing. All three mechanisms could theoretically 
act on pRBC or merozoites; however, assessing the importance of these in vivo has been challenging.  
Here, the most common in vivo models of humoral immunity to malaria, P. yoelii 17XNL and 
PcAS infection in C57BL/6 mice was used to dissect how parasite-specific antibodies elicited via 
primary infection, could control parasite numbers during a secondary challenge. This was combined 
with an RBC adoptive transfer technique to study parasite clearance and replication in vivo [134, 144, 
212]. By tracking a single cohort of fluorescent-labeled pRBC, and their resultant progeny, it was 
evident that effective control of pRBC numbers by infection-induced antibodies in two models was 
mediated not by targeting clearance of pRBC by the host, but by preventing parasites transitioning 
from one generation of RBC to the next. Moreover, it provided in vivo evidence that phagocytes are 
necessary for these antibodies to optimally block transit of parasites between RBCs. Complement-
mediated direct killing via formation of membrane attack complex (MAC) did not play any 
appreciable role; however, we did not examine C1q block in our study. Thus, data generated from 
these in vivo experiments supports the view that antibodies targeting merozoites for their phagocyte-
dependent control play an important role in controlling blood-stage Plasmodium infection, although 
C1q complement mediated blocking may also play a role in parasite control. 
Although the study demonstrated a role of phagocytes in preventing parasites transitioning 
from one generation of RBC to the next, it remains to be determined which of the two main 
phagocyte-dependent mechanisms - opsonic phagocytosis or ADCI was involved. Given that ADCI 
is mediated in vitro by a monocyte-derived cytokine, Tumor Necrosis Factor (TNF)[213], future 
studies could explore an in vivo requirement for TNF in our system. Another important question 
arising from the partial decline in antibody-efficacy after phagocyte depletion is whether the partial 
effect was due to incomplete depletion of phagocytes by clodronate liposomes, or it indicated the 
existence of multiple mechanisms of actions of antibodies. Although it is understandable that a single-
dose of clodronate liposomes is not likely to completely deplete phagocytes for more than a few days, 
it nonetheless remains a very efficient way to remove phagocytes.  For this reason, it is considered 
that other mechanisms likely contribute to pRBC control in these models, and blockade of merozoite 
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invasion is the most likely [214]. Future experiments and technological advances may be required to 
assess this mechanism since it is not currently possible to reliably visualise invasion of RBC by 
merozoites in vivo. A recent study has, however, reported successful isolation of viable merozoites 
from rodent malaria and demonstrated invasiveness of merozoites [215].  
A recent study in human samples found that the capacity of merozoite-specific antibodies to 
facilitate deposition of the polymeric complement C1q complex strongly correlated with protection 
from high-density parasitemia [214]. Additionally, in vitro assays indicated that although C1q 
deposition could increase direct complement-mediated lysis of merozoites, C1q deposition alone, i.e. 
with no other components of the complement system present, was sufficient to enable antibodies to 
block the invasion of RBC by merozoites. The study thus concluded that merozoite-specific 
antibodies protected children against high-density parasitemia probably by blocking invasion, and 
not by direct complement-mediated lysis of merozoites. Our study in mice also supported a crucial 
role of merozoite-targeting IgG in blocking transition to the next generation of RBC, with no major 
role of complement-mediated direct lysis.  However, we did not directly assess the role of antibody-
mediated C1q deposition in our study. Thus, examining whether parasite-specific antibodies are 
impaired in their capacity to block Gen0 to Gen1 transit in C1q
-/- mice would be important in future 
studies. Another important question is whether the complement system was adequately functional in 
the genetic background of C57BL/6J employed in our study, to compare similarities with human 
immunity to malaria.  A previous assessment of complement in numerous inbred mouse strains 
focused on the capacity to directly lyse cellular targets [216]. In view of these earlier findings, it was 
perhaps surprising that in our system direct complement-mediated lysis was not an important 
mechanism in controlling infection. As the levels of C1 proteins are likely equivalent amongst most 
mouse strains [216], it remains to be determined whether C1q deposition contributes to antibody 
function in the Py17XNL and PcAS systems.  We hypothesised this to be the case since a previous 
report showed that genetic C1q deficiency in mice was associated with impaired immunity to re-
challenge with blood-stage Plasmodium parasites [217]. 
Many, but not all of the suggested mechanisms by which antibodies could serve to control 
pRBC numbers in vivo can be explored during Py17XNL infection in mice. For example, it has been 
suggested that antibodies could prevent cyto-adherence, and thus sequestration of pRBC to 
endothelial surfaces in various tissues [218, 219]. Similarly, antibodies could prevent adherence of 
RBC to each other, also known as rosetting [218, 219]. Neither of these two phenomena is well-
established in the Py17XNL model.  Therefore, this data cannot be taken as complete assessment and 
understanding of all the mechanisms by which antibodies could prevent malaria in P. falciparum or 
P. vivax-infected humans.  Instead, the findings of the study suggest that targeting pRBC by 
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antibodies through binding to the erythrocyte surface is not necessary for robust control, and that 
prevention of transit from one RBC to another, possibly by targeting merozoites, predominates in the 
two most commonly used mouse models of antibody-mediated immunity. It has previously been 
shown that Py17XNL parasites export variant surface proteins, yirs, to the surface of RBC during in 
vivo infection of mice. Moreover, yirs are clearly detected by the mouse immune system, and their 
variation is dependent upon the presence of adaptive immunity [220, 221]  In our study, we observed 
that intact schizont stage pRBC did bind some parasite-specific IgG. It is possible that yirs proteins 
could be the target for such antibodies, in a similar way that PfEMP1 appears to be a major target for 
pRBC binding antibodies in human samples [222]. However, an important question that emerges 
from our study is why the IgG response to infection was dominated by antibodies specific to the 
contents of permeabilised schizonts, most likely merozoites and proteins released into circulation 
during rupture, and not to pRBC surface proteins. The answer to this question remains currently 
unknown due to the facts that antigenic variations is a major feature of pRBC surface proteins, which 
could be related to the ability of antigen-presenting cells to access and process pRBC surface proteins 
compared to merozoite proteins and the cellular debris released by pRBC rupture.  
The findings of this study also raise the question as to how antibody-mediated immunity might 
be boosted in a rational manner. For example, could increasing the plasma concentration of antibodies 
that recognise pRBC further improve protection? This may indeed be the case; however, since 
antigenic variation is a major feature of pRBC surface proteins, it will likely be challenging to induce 
pRBC-targeting antibodies that elicit long-lasting immunity to high-density parasitemia in humans. 
Nevertheless, the data using two major in vivo models of antibody-mediated immunity to blood-stage 
infection suggest that pRBC clearance is not a crucial mechanism for naturally-acquired antibodies 
in controlling parasitemia.  Instead, this data is consistent with the suggestion that binding of affinity-
matured IgG to the surface of merozoites could be highly protective against blood-stage Plasmodium 
infections in vivo via multiple mechanisms including those employing phagocytic cells. We could not 
infer whether these antibodies are merozoite binding; an Immune Fluorescent Assay (IFA) might be 
needed to explore the binding specificity in greater details. However, these pre-clinical in vivo data 
provide further insight into the types of antibody functions that might protect naturally-exposed and 
immunized humans against malaria. It is noted, due to time constrains during my PhD, I was unable 
to purify IgG from immune serum, and provide definitive proof that parasite specific IgG was indeed 
responsible for control of Gen1 parasite numbers. Instead, individual batches of immune serum were 
quality controlled by performing parasite-specific IgG ELISA, and ensuring that each batch passed a 
threshold titre. Immune serum was not heat inactivated. It should be noted that subsequent to the 
submission of this thesis, IgG purification was completed, and confirmed as being productive in our 
models. 
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Chapter Five: 
Developing a high-throughput in vivo screen for Plasmodium genes that mediate 
interaction with the host immune system 
5.1 Abstract 
The severity of malaria is often associated with the total number of Plasmodium parasites 
present in the body during infection. It is likely that both host and parasite genetic factors are involved 
in determining parasite dynamics in vivo. However, our understanding of parasite genes that control 
interactions with mammalian hosts is limited, particularly since a large portion of the Plasmodium 
genome still lacks functional annotation. Despite this, it is clear that Plasmodium genes mediate 
remodeling of host RBC, particularly via proteins exported out of the parasite itself. Hundreds of 
Plasmodium genes encode for exported genes, which are known collectively as the “exportome”. 
While some of these have been well characterised, the precise functions of many remain completely 
unknown. Therefore, the aim of my work was to develop an in vivo methodology to screen parasite 
genes required for host interaction. Using P. berghei ANKA infection of wild-type and immune-
deficient C57BL/6j and BALB/c mice, I screened 117 genes in vivo using an established high-
throughput barcode-based sequencing approach. Of these genes, 32 were identified as essential for 
parasite growth regardless of host immune status. Importantly, 8 of the essential genes had no 
previous functional annotation. Most importantly, 10 mutants were out-competed from the pool of 
117 knock-out parasites in wild-type mice, yet grew well in immune-deficient mice. One of these 
genes encodes PTEX88, a component of the molecular machinery that translocates parasite proteins 
out of the parasite itself [223]. Further analysis of inducible ptex88 knockdown parasites suggested 
that PTEX88 might play a role in governing parasite maturation within RBCs.  Thus, this study 
provided proof-of-concept that parasite genes do indeed exist that are important for blood-stage 
survival only in the presence of a fully functioning immune system.   
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5.2 Introduction 
The emergence of resistance to anti-malarial drugs and the lack of an effective vaccine to 
prevent malaria highlight the urgent need for the development of targeted malaria intervention. 
During blood-stage malaria, the merozoite form of the Plasmodium parasite infects host RBCs and 
transports proteins to sub-cellular locations. These Plasmodium-exported proteins remodel the host 
RBC to enhance parasite virulence, thereby increasing the pathogenesis and severity of the disease.  
During the remodelling process, many structural and biochemical changes occur throughout 
the parasite life-cycle that include development of a tubulovesicular network in the host cell that sorts 
and distributes exported proteins to target locations beyond its own plasma membrane (PM) and the 
parasitoporous vacuole membrane (PVM); and other membrane-bound structures formed during the 
development of this network, including Maurer’s clefts (MCs) [61], electron-dense vesicles (~80 nm 
diameter) [62, 63], J-dots [64] and knob associated histidine-rich proteins (KAHRP) and PfEMP1 
[66]. The PfEMP1 protein family is antigenically diverse as they are encoded by 60 var (variable) 
genes per haploid genome [67-70]. Several other exported parasite surface proteins, such as members 
of the RIFIN, STEVOR and SURFIN families, also exhibit antigenic variation [224, 225]. Some of 
these exported proteins, e.g. ring-infected erythrocyte surface antigen (RESA) and PfEMP3 are 
associated with the RBC cytoskeleton beneath the plasma membrane [226-228]. 
The genomes of Rodent Malaria Parasites (RMP) contain an average of 5,500 genes. A 
number of multi-gene families in RMP encode exported proteins, and these are mostly sub-telomeric 
[229]. However, more than 50% of Plasmodium genes have unknown function since their AT-rich 
genome was difficult to engineer in E. coli systems due to poor flanking sequences and the low rate 
of homologous recombination for reverse genetics studies. Reduced number of selection markers has 
also been a limiting factor, especially for P.berghei studies in which drug toxicity for the animals was 
an issue. Only a small percentage of genes that encode exported proteins have been previously 
investigated [230, 231]. 
Our collaborators (Dr. Oliver Billker, Wellcome Trust Sanger Institute) recently developed a 
method for reverse genetic screening of the Plasmodium berghei genome [138] by creating an open-
access Plasmodium genetic modification resource, PlasmoGEM, which includes knock-out vectors 
that integrate efficiently along with gene-specific molecular barcodes [232]. Here, I studied export 
protein-related genes using PlasmoGEM resources.  
Firstly, 1,818 genes coding for putative exported proteins were identified in silico prior to my 
project based on 1) export prediction, 2) putative transmembrane domain, 3) published sequence 
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phenotype, 4) PEXEL orthologue, 5) signal peptide, 6) translocon components, 7) Maurer’s cleft/ 
sequestration genes, 8) Van Ooji conserved exportome or 9) rodent malaria parasite only synteny. 
Following score-based selection, 289 out of the total 1,818 genes coding for putative exported 
proteins were positive for at least 3 criteria and were selected for characterisation. Knock-out 
PlasmoGEM vectors for 117 genes were successfully generated from 289 candidates prior to the 
initiation of my project (refer to Flowchart 1). 
Flowchart 1: Selection process of 117 genes  
 
 
PlasmoGEM vectors were designed with long homology arms for efficient genome 
integration and carried gene-specific barcodes to identify individual mutants within a pool [232]. 
Vectors were generated from Plasmodium berghei ANKA (PbA) genomic DNA libraries (PbG) 
through a sequential, two-step process, which utilises recombinase-mediated engineering 
(recombineering) and Gateway technology [138]. The positioning of the recombineering primers 
determined the gene targeting strategy. A molecular barcode consisting of 11 variable nucleotides, 
flanked by 20 invariable nucleotides (that constituted primer annealing sites for PCR amplification), 
were introduced into each of the PlasmoGEM vectors. A common pair of PCR primers was used to 
amplify the barcode module from all PlasmoGEM constructs. The barcodes permitted identification 
of each vector, and therefore, each transgenic parasite by next-generation sequencing on an Illumina 
sequencer, a technique referred to as barseq. It has recently become possible to measure individual 
1818 putative exported proteins
(based on In silico identification based on criteria
such as export prediction, transmembrane domain,
PEXEL etc.)
~ 300 genes selected based on criteria scored >3
Finally 117 KO vectors were ready to screen
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growth rates within parasite pools composed of different mutants in the blood of a single mouse. 
Hence, analysis of mixed populations of mutants using barcode technology provides two major 
advantages: 1) acceleration of the Plasmodium genome screening process and 2) significant reduction 
in cost and animal usage.  
 
 
Figure 5.1 Schematic representation of knockout vector design. 
Note:  The design and preparation of the vectors was performed by the PlasmoGEM team at the Sanger 
institute. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5’ homology arm 3’ homology arm
5’…aggggtgttgt…3’ gene specific barcode
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5.3 Results 
5.3.1 Detecting small numbers of bar-coded KO parasites in the blood and tissue of mice 
5.3.1.1 Mutants can be detected in tissues using barseq analysis 
One important aspect of parasite interaction with mammalian hosts, not only for Plasmodium 
falciparum in humans but also for PbA in mice, is the potential for parasites to accumulate in 
microvasculature in various tissues.   This process is termed “sequestration” in human malaria and is 
generally defined by the discovery of specific ligand/receptor interactions, such as chondroitin 
sulphate A/PfEMP1 interactions in pregnancy-associated placental sequestration. In my project, I 
hypothesized that certain exported proteins might be required not for growth in the blood-stream, but 
for accumulation in tissues. Therefore I predicted that certain KO parasites would be more abundant 
in the bloodstream than they would be amongst sequestered parasites in tissues.  To test this 
hypothesis, it was first necessary to determine if parasite barcodes from PlasmoGEM vectors could 
be detected reliably in organs from infected mice since mutants had previously only been assessed in 
circulating blood [233]. Before screening large numbers of genes, I first investigated whether a small 
number of bar-coded mutants could be detected in various tissues of mice. Five mutants with known 
sequestration phenotypes were employed: 1) EMAP1 (erythrocyte membrane-associated protein), 
which is a member of the PEXEL-negative protein family, and has no known role in parasite 
sequestration [234]; 2) MIF (Macrophage migration inhibitory factor) is homologous to mammalian 
MIF, which modulates the immune response against blood-stage parasites, is located in the cytoplasm 
of the parasite, and has no known role in sequestration [235]; 3) TRX2 (Thioredoxin 2 protein), is a 
core component of the Plasmodium translocon of exported proteins (PTEX) and acts to unfold 
proteins for translocation [223]; 4) PTEX88 is another core component of PTEX involved in the 
sequestration of pRBC and cerebral malaria [223]; and 5) SBP1 (Skeleton Binding protein 1) is 
transmembrane protein that induces the formation of membranous structures within the pRBC 
cytoplasm called Maurer’s Clefts (MC) and its main function is to position PfEMP1 on the RBC for 
cyto-adherence (i.e. protein-protein interaction) [236]. Given that PTEX88, TRX2, and SBP1 are all 
well-known exported proteins with published roles in disease severity in PbA infections, these three 
KO parasites were hypothesized to be outcompeted in tissues compared to the blood-stream. 
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Figure 5.2 Detecting mixed populations of mutants in blood and tissues. Mice (n= 3) were infected 
with 100 µl of 5 pooled PbA knock-out mutants and placed under pyrimethamine drug selection. 
Blood samples were collected on days 1- 4 p.i., and organs on day 4 p.i. after perfusion of CO2 
euthanised mice. Experiment conducted once. 
 
Mice were infected with 100µl of blood containing a pool of 5 mutants, each isolated from 
individual transfections and subsequently mixed together. On day 0 mice were placed under 
pyrimethamine drug selection and blood was collected on day 1- 4 p.i. and tissue samples were 
collected on day 4 p.i for DNA extraction (Figure 5.2). The samples were then processed for barcode 
sequencing and analysis. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3 Mutants were present in blood as expected. Average blood-stage growth rate of 5 known-
phenotype barcoded PbA KO mutants (n=3).  
 
I first examined the ability of the 5 mutants in the pool to be detected in the blood.  Having 
determined the relative abundance of each mutant within the pool, I next calculated a metric termed 
“growth rate” (Figure 5.3). I defined this to be the fold-change in the relative abundance of a mutant 
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from one day to the next (e.g from day 1 to day 2, or day 2 to day 3) (the calculation is given in 
methods section). Emap1 and Mif, which were known to be non-essential for blood-stage growth, 
exhibited slightly higher growth rates than the other three mutants over the course of infection. In 
particular, sbp1 and ptex88 KO parasites had reduced growth rates compared to Emap1 and Mif. This 
data first confirmed my own capacity to detect mutants within a pool, and furthermore confirmed 
reduced growth rate fitness, as expected, for parasites lacking sbp1 or ptex88.  
 
Having confirmed detection of KO parasites in the blood, I next determined whether KO 
parasites could be detected in tissues. In order to detect KO parasites in tissues, on day 4 p.i., multiple 
tissue samples (spleen, lung, heart, brain, liver, kidney and adipose tissue) were harvested from mice 
after removing circulating blood by perfusion of CO2 euthanized mice. DNA was extracted from 
tissue samples and PCR used to amplify barcodes, prior to sequencing. 
 
 
 
 
 
 
 
 
 
 
Figure 5.4 Mutants relative abundance of in blood and different tissues. Mutants accumulate in 
tissues in accordance to blood relative abundance. 
 
The relative abundance of a mutant in different tissues showed the same pattern for the relative 
abundance of that mutant in the blood (Figure 5.4). As the relative abundance of Mif and Emap1 were 
high in the blood, their relative abundance was also high in the tissues. Furthermore, tissues that are 
associated with parasite accumulation demonstrated increased relative abundances of most mutants 
in comparison to other tissues. For example, we found that adipose tissue had a high relative 
abundance of a mutant when the relative abundance was also high in the blood. However, adipose 
tissue showed low relative abundances when the mutant demonstrated a low abundance in the blood 
and this similar phenomenon was observed for ptex88, and sbp1. Therefore, our findings 
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demonstrated that the barcode based sequencing approach is indeed capable of detecting KO mutants 
in tissue as well as blood and that the relative growth rates and abundance of KO mutants is consistent 
with known phenotypes. 
5.3.2 Screening 117 genes to explore their role in blood-stage infection  
Here, it was hypothesised that parasite genes that encoded for exported proteins might be 
required for blood-stage growth, and interact with host factors. If a particular gene is important for 
interacting with the host immune system, then a KO mutant for that gene will be lost from the pool 
of mutants in the immune-competent host. Therefore, the wild-type mice C57BL/6J and BALB/c and 
their corresponding immune-deficient mice rag1-/- and SCID, which are mainly deficient of T and B 
cells, were used for screening of 117 genes. The detailed experimental procedure has been described 
in the material and methods (sub-section 2.4.14) and schematic representation (Figure 5.5). Briefly, 
the pool of KO vectors DNA was transfected into purified schizonts using the Lonza 4D-Nucleofactor 
system. Then the transfection mixture was immediately injected intravenously into the tail veins of 
6-8 week old C57BL/6J, rag1-/-, Balb/c, and SCID mice. After 24 hours of infection, mice were placed 
under drug selection. Blood samples were collected on days 4-7 p.i. and organs on day 7 p.i. after 
perfusion of CO2 euthanized mice. Blood and tissue DNA was used for PCR amplification of 
barcodes, with an index primer used to tag each sample for individual identification, and then samples 
were sequenced by next-generation sequencing for barcode counting analysis.  
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 Figure 5.5 Schematic representation of screening of 117 KO vectors using barcode-based 
sequencing assay.  Trnasfetion was done once the pool of knock-out vectors DNA and schizonts were 
ready and mice were infected with transfected DNA via tail intravenously injection. Parasitemia 
monitored on day 4 p.i. and blood and tissue samples were analysed for barcode quantification. 
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Table 1: List of PlasmoGEM identification numbers for vectors used in the experiments 
 
 
 
 
Gene ID Annotation
PBANKA_131800 serine/threonine protein kinase, putative
PBANKA_133500 conserved Plasmodium protein, unknown function
PBANKA_062320 lysophospholipase, putative
PBANKA_052430 tryptophan/threonine-rich antigen, putative
PBANKA_132380 conserved Plasmodium protein, unknown function
PBANKA_062310 Plasmodium exported protein, unknown function
PBANKA_132800 serine/threonine protein phosphatase, putative
PBANKA_041065 conserved Plasmodium protein, unknown function
PBANKA_133490 conserved Plasmodium protein, unknown function
PBANKA_112510 3-oxoacyl-acyl-carrier protein synthase, putative
PBANKA_101610 peptide chain release factor 1, putative
PBANKA_050260 conserved Plasmodium protein, unknown function
PBANKA_113970 conserved Plasmodium protein, unknown function
PBANKA_141030 M1-family alanyl aminopeptidase, putative
PBANKA_061580 exported serine/threonine protein kinase
PBANKA_140070 Plasmodium exported protein, unknown function
PBANKA_052320 serpentine receptor, putative
PBANKA_133090 conserved Plasmodium protein, unknown function
PBANKA_090790 conserved Plasmodium protein, unknown function
PBANKA_124660 fam-b protein cleft-like protein 1
PBANKA_020760 asparagine-rich antigen, putative
PBANKA_133810 conserved Plasmodium protein, unknown function
PBANKA_070100 tryptophan-rich antigen, putative, pseudogene
PBANKA_140060 cytoadherence linked asexual protein, putative
PBANKA_031000 heat shock 40 kDa protein, putative
PBANKA_123820 DnaJ protein, putative
PBANKA_083610 phosphatidylinositol N-acetylglucosaminyltransferase subunit P, putative
PBANKA_071420 ClpB protein, putative
PBANKA_061060 peripheral plastid protein 1, putative
PBANKA_093120 heat shock protein 101, putative
PBANKA_093830 heat shock protein, putative
PBANKA_082630 thioredoxin-like protein 2, putative
PBANKA_132070 signal peptide peptidase, putative
PBANKA_010780 citrate synthase-like protein, putative
PBANKA_052480 early transcribed membrane protein small exported protein
PBANKA_031660 reticulocyte binding protein, putative
PBANKA_110430 conserved Plasmodium protein, unknown function
PBANKA_120070 conserved Plasmodium protein, unknown function
PBANKA_100390 sexual stage-specific protein precursor, putative
PBANKA_133270 duffy-binding protein
PBANKA_050120 up-regulated in infective sporozoites early transcribed membrane protein
PBANKA_111760 conserved Plasmodium protein, unknown function
PBANKA_083210 conserved Plasmodium protein, unknown function
PBANKA_110140 rhoptry-associated protein 2/3
PBANKA_110500 conserved Plasmodium protein, unknown function
PBANKA_092770 conserved Plasmodium protein, unknown function
PBANKA_100010 reticulocyte binding protein, putative
PBANKA_091510 LEM3/CDC50 family protein, putative
PBANKA_134910 merozoite surface protein 7
PBANKA_070440 alpha/beta hydrolase, putative
PBANKA_133690 conserved Plasmodium protein, unknown function
PBANKA_021460 Plasmodium exported protein, unknown function
PBANKA_100760 conserved Plasmodium protein, unknown function
PBANKA_104030 fam-b protein
PBANKA_021550 erythrocyte membrane associated protein 2
PBANKA_120060 Plasmodium exported protein, unknown function
PBANKA_050100 reticulocyte binding protein, putative
PBANKA_051700 early transcribed membrane protein
PBANKA_100060 erythrocyte membrane antigen 1
PBANKA_120520 conserved membrane protein, unknown function
PBANKA_122090 conserved Plasmodium protein, unknown function
PBANKA_131150 conserved Plasmodium protein, unknown function
PBANKA_070070 Plasmodium exported protein, unknown function
PBANKA_050060 fam-b protein
PBANKA_124380 apicoplast TIC22 protein, putative
PBANKA_041850 Plasmodium exported protein, unknown function
PBANKA_140040 fam-b protein
PBANKA_100850 translocon component PTEX150
PBANKA_060990 Pbj4
PBANKA_135800 thioredoxin 2
PBANKA_102390 glutathione S-transferase, putative
PBANKA_094130 translocon component PTEX88, putative
PBANKA_122020 lysophospholipase, putative
PBANKA_133220 translation initiation factor IF-1, putative
PBANKA_133870 plasmepsin V, putative
PBANKA_134540 ER lumen protein retaining receptor 1, putative
PBANKA_110090 fam-a protein
PBANKA_110100 fam-a protein
PBANKA_090270 leucine-rich repeat protein
PBANKA_120790 protein phosphatase, putative
PBANKA_133430 exported protein 2, putative
PBANKA_104020 BIR protein
PBANKA_051900 S-antigen, putative
PBANKA_140330 phosphatase, putative
PBANKA_030060 Plasmodium exported protein, unknown function
PBANKA_020890 conserved Plasmodium protein, unknown function
PBANKA_062350 fam-a protein
PBANKA_083680 erythrocyte membrane associated protein 1 fam-a protein
PBANKA_100120 conserved Plasmodium protein, unknown function
PBANKA_070120 conserved Plasmodium protein, unknown function
PBANKA_080040 conserved Plasmodium protein, unknown function
PBANKA_010220 trophozoite exported protein 1, putative
PBANKA_120710 Plasmodium exported protein, unknown function
PBANKA_010720 conserved Plasmodium protein, unknown function
PBANKA_120820 conserved Plasmodium protein, unknown function
PBANKA_060880 conserved Plasmodium protein, unknown function
PBANKA_100860 conserved Plasmodium protein, unknown function
PBANKA_051080 conserved Plasmodium protein, unknown function
PBANKA_111210 conserved Plasmodium protein, unknown function
PBANKA_041540 conserved Plasmodium protein, unknown function, pseudogene
PBANKA_041190 conserved Plasmodium protein, unknown function
PBANKA_061310 conserved Plasmodium protein, unknown function
PBANKA_051810 conserved Plasmodium protein, unknown function
PBANKA_132420 conserved Plasmodium protein, unknown function
PBANKA_082420 perforin-like protein 3
PBANKA_102910 conserved Plasmodium protein, unknown function
PBANKA_082530 conserved Plasmodium protein, unknown function
PBANKA_143540 conserved Plasmodium protein, unknown function
PBANKA_132960 conserved Plasmodium protein, unknown function
PBANKA_113870 conserved Plasmodium protein, unknown function
PBANKA_083660 fam-b protein
PBANKA_144790 conserved Plasmodium protein, unknown function
PBANKA_135130 conserved Plasmodium protein, unknown function
PBANKA_110130 Putative SBP1
PBANKA_114590 Putative MAHRP1b
PBANKA_131910 Haemolysin 3
PBANKA_010060 schizont membrane associated cytoadherence protein (SMAC)
89 
 
5.3.2.1 Validation of vectors  
To confirm that all the selected vectors were present during transfection, a small aliquot of 
the transfection mixture was collected after electroporation by washing the electroporation wells of 
the 16-strip Amaxa 4D. This wash was then used as an input sample, thus acting as a positive control 
for the presence of vectors in the vector pool and also as an internal control for sample cross-
contamination. 
Vectors for seven control mutants (4 normal growing and 3 slow growing) were spiked into 
the pooled DNA of 117 KO vectors, making up the total of 124 transfected vectors in the pool. 
However, we only recovered 117 vectors (94%) in the input sample (depicted in Flowchart 3). A 
small number of vectors were lost, possibly because of the insufficient DNA of those specific vectors.  
Flowchart 3: Presence of vectors DNA in the input samples  
 
  
Further analysis of the vector-specific barcode counting of the input pool DNA revealed that 
81% of the vectors present in the input samples had a relative barcode abundance of approximately 
Vectors in pool (117 KO vectors  +  7  controls = 124 )
Vectors in input samples (110 KO vectors  +  7  controls = 117)
Vectors were not present in the DNA pool
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400-500 (Figure 5.6) with 10% above or below the average line (note: one mutant was considered an 
outlier). Importantly, most of the vectors were present in relatively constant proportions in each input 
sample indicating that the DNA preparation in a pooled midiprep did not overtly bias the experiment 
(Figure 5.6). 
 
 
 
 
 
 
 
 
Figure 5.6 Relative abundance of vectors in the input sample. The input sample was collected from 
the electroporation cuvette after transfection and measured the proportion of each vector present in 
the vector pool during transfection. 
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5.3.2.2 Parasites grew normally in all mouse strains  
Schizonts were transfected with the pool of vector DNA in twelve batches, and each batch 
was immediately injected intravenously into mice (n=3) of each four different mouse strains (i.e. 
C57BL/6J, Rag1-/-, Balb/c, and SCID). After 24 h of infection, mice were placed under drug selection 
to eliminate wild-type parasites, and infections were monitored from day 5-7 p.i. using Giemsa-
stained thin blood films. Data showed that overall parasites grew in a similar manner in all four groups 
of mice (Figure 5.7). 
 
 
 
 
 
 
             
 
 
 
 
 
Figure 5.7 Mutant parasites grew similarly in all four mouse strains. Transfected PbA schizonts 
were intravenously injected into C57BL/6J, rag1-/-, Balb/c and SCID mice (n=3). Parasitemia was 
monitored on days 5-7 p.i. using Giemsa-stained thin blood films.  
 
5.3.2.3 Normal and slow growing control mutants had corresponding fitness values  
Mutants of four genes known to be non-essential for asexual parasite growth were included 
in the pool of 117 genes “as reference genes” (normal growing controls) for comparing the growth 
rates of all other mutants. This reference set consisted of two knockout vectors for the major surface 
proteins of ookinetes, P25 and P28 [237]; another knockout vector for a secreted ookinete adhesive 
protein, soap [238]; and a C-terminal tagging vector for the redundant p230 gene [239]. In addition, 
knock-out vectors of three genes of slow-growing controls, namely plasmepsin iv, bckdh 
(PBANKA_110420), and a putative methyl transferase (PBANKA_140160) were also included to 
identify mutants with reduced growth rates in a more accurate manner. Plasmepsin IV is an aspartic 
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protease involved in the degradation of hemoglobin. It has been reported that deletion of plasmepsin 
IV gene in the P. berghei genome resulted in attenuated growth [240]. PBANKA_110420 encodes 
the E1β subunit of the mitochondrial branched-chain α-ketoacid dehydrogenase (BCKDH) [241], and 
this was used because deletion of the E1α subunit of the same complex has a clear growth phenotype. 
The third attenuating knock-out vector targeted PBANKA_140160, a putative methyl transferase of 
unknown function, which demonstrated a slow-growing mutant phenotype [139]. Their growth 
phenotypes were quantified by calculating their mean relative fitness values as described in Materials 
and Methods (subsection 2.4.19). The normal growing control mutants were redundant for asexual 
blood-stage growth and grew over the course of infection with a mean relative fitness close to 1 (green 
line) as wild-type parasite fitness. The slow-growing control mutants showed reduced parasite fitness, 
with values between 0.60 and 0.73 (orange line) (Figure 5.8).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8 Fitness of normal and slow growing control mutants in blood. The four mutants of 
normal growing control genes, which were redundant for asexual blood-stage growth, grew 
increasingly over the course of infection with a mean relative fitness close to 1 (green line) as wild-
type parasite fitness. The attenuated slow growing control mutants showed a measureable reduction 
in parasite fitness, with values between 0.60 and 0.73 (orange line).5.3.2.4 Distribution of mutants 
in individual mouse strains. 
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When a target gene is essential for blood-stage growth, mutant parasites will die and the 
corresponding barcodes will disappear from circulation either by lysis or by splenic clearance. 
Therefore, those genes with no barcode evidence on day 4 p.i. may be considered as essential genes 
for growth. However, there may be false negative results due to vectors that were unable to integrate 
into the parasite genome. Thus, to use more accurate terminology, genes with barcode levels that 
were below the detection threshold on day 7 p.i. were referred as “likely essential”. Four mutant 
phenotypes were identified relative to the normal growing (fitness value = 1) and slow growing 
(fitness value = 0.6-0.7) control mutants: likely essential mutants - if there was no barcode for a 
specific mutant in any of the 3 mice on day 7 p.i.; slow growing with fitness values between 0.1 and 
1.0; likely dispensable with fitness values of 1.0; and fast-growing with fitness values > 1.0. A mutant 
was included in this distribution analysis if it had a fitness value in at least two out of three infected 
mice (Figure 5.9). 
 
 
 
 
 
 
 
Figure 5.9 Distribution of mutants in 4 mouse strains (BALB/c, SCID, C57BL/6J and Rag1-/-) 
based on fitness value. The fitness value for normal growing mutants is 1 and designated as likely 
dispensable genes (green), while slow growing mutants have fitness values between 0.1 and 1 
(orange) and mutants for likely essential genes have fitness values less than 0.1(red).  
 
In the screening of 117 genes using this high through-put barcode sequencing approach, we 
found 32 genes were likely essential for parasite growth as there was no evidence of their 
corresponding barcodes in parasites circulating in the blood of any of the 4 groups of mice. Moreover, 
eight of these likely essential genes were completely novel because they were annotated only as 
conserved Plasmodium protein of unknown function. Therefore, these eight likely essential genes 
were selected for further study (boxed in Table 2). Interestingly, it has observed that the most of genes 
were either likely essential or were important for growth in the C57/Bl6 compared to Balb/c, which 
might be due to the differences in the immune responses between Balb/c and C57BL/6.  
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Table 2: Likely essential genes for blood-stage growth in malaria
 
Barcode Gene ID Annotation C57BL/6J Rag1-/- Balb/c SCID
gcatttcatgt PBANKA_010060 Schizont membrane associated cytoadherence protein (SMAC) 0 0 0 0
aagccaggacg PBANKA_010780 Citrate synthase-like protein, putative 0 0 0 0
aggctctggct PBANKA_020760 Asparagine-rich antigen, putative 0 0 0 0
gtcgcacccga PBANKA_020890 StAR-related lipid transfer protein, putative 0 0 0 0
tgtgcaggtgc PBANKA_030060 Plasmodium exported protein, unknown function 0 0 0 0
tgttgccataa PBANKA_050260 Conserved Plasmodium protein, unknown function 0 0 0 0
cagccccatac PBANKA_060990 Heat shock protein DNAJ homologue Pfj4, putative 0 0 0 0
gggtgggttga PBANKA_061060 Peripheral plastid protein 1, putative (PPP1) 0 0 0 0
gactttaagaa PBANKA_061310 Conserved Plasmodium protein, unknown function 0 0 0 0
caaagaaaaag PBANKA_061580 Exported serine/threonine protein kinase (EST) 0 0 0 0
aaatgggcgcg PBANKA_062310 Plasmodium exported protein, unknown function 0 0 0 0
ggtacgtagcc PBANKA_071420 Chaperone protein ClpB1, putative (ClpB1) 0 0 0 0
tcaggcgtacc PBANKA_082630 Thioredoxin-like protein 2, putative (TLP2) 0 0 0 0
acttgtgctgc PBANKA_083610
Phosphatidylinositol N-acetylglucosaminyltransferase subunit P, 
putative
0 0 0 0
ctcttttgaat PBANKA_093120 Heat shock protein 101 (HSP101) 0 0 0 0
ccaatcattat PBANKA_093830 Heat shock protein, putative 0 0 0 0
gtctcttttcg PBANKA_100850 Translocon component PTEX150 (PTEX150) 0 0 0 0
cgagattagtc PBANKA_110130 Conserved rodent malaria protein, unknown function 0 0 0 0
ccgctcgttag PBANKA_110500 Conserved Plasmodium protein, unknown function 0 0 0 0
acgggttcaac PBANKA_113970 Conserved Plasmodium protein, unknown function 0 0 0 0
aaaatgatcgg PBANKA_120820 Kinesin-4, putative 0 0 0 0
ggattccgcgt PBANKA_132070 Signal peptide peptidase, putative (SPP) 0 0 0 0
ctggcctcgtt PBANKA_132800 Serine/threonine protein phosphatase, putative (UIS2) 0 0 0 0
aaaccatcctc PBANKA_133220 Translation initiation factor IF-1, putative (IF1) 0 0 0 0
tggactgagtc PBANKA_133270 Duffy-binding protein 0 0 0 0
aggttctaccc PBANKA_133430 Exported protein 2 (EXP2) 0 0 0 0
cgcggctgtct PBANKA_133870 Plasmepsin V, putative (PMV) 0 0 0 0
tcggacggttg PBANKA_134540 ER lumen protein retaining receptor 1, putative 0 0 0 0
agtgcgccact PBANKA_140060 Cytoadherence linked asexual protein, putative 0 0 0 0
ttcatccccag PBANKA_140330 NLI interacting factor-like phosphatase (NIF1) 0 0 0 0
attttcatctg PBANKA_141030 M1-family alanylaminopeptidase, putative (M1AAP) 0 0 0 0
ccaagacgcga PBANKA_143540 Conserved Plasmodium protein, unknown function 0 0 0 0
Fitness value on day 7 
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Furthermore, we identified 10 mutants that did not grow in C57Bl/6J wild-type mice but grew 
well in immune-deficient mice Rag1-/- mice. Since mutants of these genes did not grow in immune-
competent mice, this suggested that these genes were crucial for blood-stage parasite growth in the 
presence of an intact immune system, whereas they were redundant in immune-deficient mice. 
Therefore, we consider them an important group of genes for future studies into host-parasite 
interactions in malaria (Table 3). The differential growth capabilities of mutants indicate that parasite 
proteins may be involved in the progression and severity of the malarial disease. This is consistent 
with a recent study that showed that ptex88-deficient P. berghei parasites no longer sequestered 
within tissues and failed to cause cerebral malaria [230].   
 
Table 3: Mutants that did not grow in C57BL/6J, but grew well in rag1-/- mice 
 
 
 
 
 
 
 
 
Barcode Gene ID Annotation C57BL/6J Rag1
-/- Balb/c SCID
caaactacgca PBANKA_070120 Conserved Plasmodium protein, unknown function 0 0.855675 0 0
ctgaatactcg PBANKA_062320 Lysophospholipase, putative 0 0.8871839 0 0.767778
tagtcctttat PBANKA_122090 Conserved Plasmodium protein, unknown function 0 0.914329 0.9275411 0.683944
ttctttgttat PBANKA_080040 Conserved Plasmodium protein, unknown function 0 0.962981 0.7633314 0.723511
tgtgttttgtt PBANKA_082530 Conserved Plasmodium protein, unknown function 0 1.0058039 0.9562367 0.750512
ttcggtatcgg PBANKA_133810 Conserved Plasmodium protein, unknown function 0 1.082715 1.1004241 1.101753
ttcggtatcgg PBANKA_133810 Conserved Plasmodium protein, unknown function 0 1.082715 1.1004241 1.101753
atccgcgtgta PBANKA_094130 Translocon component PTEX88 (PTEX88) 0 1.1458119 0 0
tttccagaata PBANKA_140070 Plasmodium exported protein, unknown function 0 1.183722 0 0.991461
ttgggtcaccc PBANKA_113870 Conserved Plasmodium protein, unknown function 0 1.2555636 0.8756698 1.129106
Fitness value on day 7 
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5.3.2.6 No difference in the presence of mutants in blood and tissues of different mouse strains  
Using my earlier work in applying barseq analysis to tissues, I next examined whether mutants 
accumulated in tissues in proportion to their presence in the blood and whether this was dependent 
on the immune status of the mice. Hence, linear regression analysis was performed on the abundance 
of each mutant in the blood and versus each tissue studied for each mouse strain on day 7 p.i. The 
abundance of normal growing (green triangle) and slow growing (orange rectangle) control mutants 
were aligned with the regression line (red line). Test mutants were similarly aligned with the 
regression line which suggested that the tissue accumulation of P. berghei mutants was related to the 
mutant’s relative abundance in the blood, regardless of immune competency (5.10).  
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 Figure 5.10 Comparison of the relative abundance of mutants in blood and tissue at day 7 p.i. The 
relative abundance of a mutant on day 7 p.i. in the blood and tissue was plotted for 4 strains of mice 
(green = normal growing control mutants, orange = slow growing control mutants, and 
black/grey=test mutants).  The plot demonstrates correlation in mutants’ abundance in blood and 
tissues regardless mouse strains. 
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5.3.3 Exploring the role of PTEX88 proteins in during blood-stage malaria  
The previous Barseq data suggested that PTEX88 was essential for parasite blood-stage 
growth in immune-competent C57BL/6J mice, but not in immune-deficient rag1-/- mice. This led us 
to further investigate how PTEX88 contributes to the PbA survival advantage in C57BL/6J mice – 
does it enable parasites to avoid clearance or does it support the development parasite life-cycle stages 
by enhancing maturation and replication rate. Thus, next, I sought to study the role of PTEX88 using 
a PbPTEX88 inducible knock-down (iKD) parasites [242] and our in vivo Clearance/Growth assay.  
5.3.3.1 Exploring the effect of PTEX88 knockdown on parasite growth in vivo 
 We used PbPTEX88iKD parasites in which PTEX88 is knocked down via the administration 
of ATc in drinking water. We first investigated whether ATc has any non-specific effects on the 
growth of wild-type parasites. Mice were infected with wild-type Pb ANKA (luciferase) and 
PbPTEX88iKD parasites and treated with either ATc (0.2mg/ml in 5% sucrose water) or control 
vehicle (5% sucrose water). Parasitemia was monitored daily from day 3 p.i., until mice developed 
clinical symptoms of cerebral malaria. We observed that ATc administration did not cause any non-
specific effect on parasitemia in mice infected with wild PbANKA compared to the control group 
(Figure 5.11A). However, ATc administration in mice infected with mutant parasites PbPTEX88iKD 
was associated with reduced parasite growth in comparison with the non ATc-treated control group 
(Figure 5.11B). The data suggested that ATc treatment had a specific effect on the growth of 
PbPTEX88iKD parasites, consistent with previous studies [243]. 
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Figure 5.11 ATc treatment effect was specific to mutant PbPTEX88iKD in vivo. Parasitemia in 
wild type (C57BL/6J) mice administered either ATc in 5% sucrose water (black line) or 5% sucrose 
(red line) after infection with PbANKA wildtype parasites (A) or PbPTEX88iKD parasites (B). Error 
bars represent SEM, p<0.01 = **.  Experiment conducted once. 
 
5.3.3.2 Gen0 parasites maturation impaired due to knock down of PTEX88  
Next, it was hypothesised that PTEX88 might have a role in parasite clearance and maturation 
through life stages. This was studied by using PbPTEX88iKD parasite and our in vivo 
Clearance/Growth assay. Here, after mice were infected with labeled pRBCs collected from a passage 
mouse infected with PbPTEX88iKD parasites, they were treated either with ATc in drinking water 
or control vehicle. Mice were tail bled at intervals between 1 and 73h post-infection, and parasitemia 
monitored by flow cytometry. Initial analysis by measuring the proportion (%) of G0 pRBCs 
(clearance) and G1+ parasites population (parasite growth) in the recipient RBCs after transitioning 
from G0 to G1+ parasites demonstrated that knocking-down of PTEX88 resulted in more G0 parasites 
to remain in circulation 25 hours after ATc treatment, as well lower numbers of Gen1 parasites 48 
hours after the knock-down (Figure 5.12). Our collaborator Rosemary Aogo and colleagues 
conducted further analyses using their mathematical model to ascertain whether the rate of parasite 
clearance or infectivity changed with PTEX88 knock down (personal communication) [244]. There 
was no significant difference in the rate of parasite clearance or infectivity between the controls and 
the ATc treatment groups. Since G0 parasites persisted for longer with PTEX88 knock down, 
modellers employed the delayed maturation model [144] to find any evidence of delayed maturation, 
and the results suggested that PTEX88 knock-down caused PbA parasites to mature at a slower rate 
(34-hour cycle) compared to controls (24-hour cycle), especially during the ring stage of the parasite 
life cycle. A recent study has reported that PTEX88 (the Plasmodium translocon of exported protein 
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88) facilitates entry of the trafficking proteins into the host cells, which is required for parasite 
development and survival. PTEX88 interacts closely with HSP101, but has weaker affinity with other 
core components of PTEX. PTEX88 is expressed during blood-stage life cycle; however, it is 
discretely found at the parasitophorous vacuole membrane during the ring stage [245]. This 
observation supports our data that PTEX88 is essential for parasite maturation, especially in the early 
stage of its life cycle and not for enabling the parasites to avoid clearance. Future experiment required 
to be conducted to understand the mechanisms involved in the slow maturation of parasites caused 
by PTEX88 knock-down, due to discrepant results in our initial and the repeat experiments. 
Moreover, delay in maturation in this model could be validated by injecting merozoites and tracking 
parasite life-stages for when next cycle of rings begins by isolation of viable merozoites. 
 
 
 
Figure 5.12 No influence of PTEX88 in the clearance and growth of parasite. C57BL/6J mice (n=5) 
injected with labelled PbPTEX88iKD RBC were treated with either 0.2mg/ml ATC in 5% sucrose 
(black) or 5% sucrose vehicle (red). (A) The graph shows reductions  in the proportion of percentage 
of G0 pRBCs (Gen0), called clearance and (B) growth of parasites (G1+ parasites population) in 
recipient RBCs after rupturing from G0 parasites in WT mice (n=5) treated with either 0.2mg/ml ATc 
in 5% sucrose or 5% sucrose vehicle. Error bars represent SEM, p<0.01 = **. Experiments 
conducted twice. 
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5.4 Discussion 
Here, first I confirmed that the barcode-based NGS sequencing approach [246] is indeed 
capable of detecting KO mutants in tissue as in blood. Then, I screened 117 exportome-associated 
genes to identify that in terms of infection outcome, particular exported parasite proteins interacted 
with the host using immune-competent and immune-deficient mice. The data revealed that 32 of 
these genes were essential for blood-stage growth regardless of mouse genetic background, including 
8 with no previous functional annotation. Further analysis revealed that 10 genes were required for 
parasite growth in the presence of an intact immune system, but were not required for parasite growth 
in immune-deficient mice. Analysis of mutant abundance in tissues of different mouse strains 
indicated that mutants accumulated in tissues in proportion to their presence in blood, despite 
differences in immune competency.  
On day 4, there was a difference between the proportions of barcodes for some mutants, 
despite similar input ratios of barcodes for those specific vectors, suggesting that some of the genes 
have roles in growth.  However, it also is possible that different vectors may integrate into the parasite 
genome with different efficiency (integration efficiency depends on the length of vectors homology 
arms and recombination rate) [139]. Thus, there may be some false negative results in the data due to 
the vectors that were unable to effectively integrate into the parasite genome. Hence, we could not 
determine with confidence whether a lack of barcodes for a particular mutant was due to the inability 
of the resultant mutant to grow or due to the inability of the vector to integrate into the genome. 
Moreover, where barcode levels were below the detectable threshold by day 7, genes were referred 
to as “likely essential”, rather than essential. From the growth curve after day 4 p.i., we can monitor 
the dynamics of mutant growth within the host. Some mutants grew increasingly over the course of 
the infection and were thus inferred to be non-essential or redundant for blood-stage growth, while 
other mutants declined in growth over the course of the infection and were, therefore, considered to 
be slow growing mutants. A limitation of this analysis is that although some mutants were growing 
on day 4 and beyond, they were continually being outcompeted by redundant knockouts and, 
therefore,  would ultimately drop below the detectable level of barseq (regardless of the actual number 
of parasites gradually growing). However, this limitation can be overcome by a second-pass screen 
that excludes most of the fast-growing (redundant) mutants [139]. 
Mutants which did not grow or had exhibited reduced growth in the model of cerebral malaria, 
C57BL/6J, but grew well in immune-deficient mice rag1-/- (T and B-cell deficient), represent one of 
the most interesting groups of genes for studying host-parasite interactions. Binding of parasite 
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proteins (presented on the surface of the iRBC following exportation from the parasite) to the host 
receptor of endothelial cells of the microvasculature leads to sequestration of iRBCs in organs and is 
responsible for severe complications in malaria, such as cerebral malaria caused by Plasmodium 
falciparum in humans. A previous study has shown that P. berghei iRBCs adhere to endothelial cells 
via binding to the receptor CD36 [129], which is also commonly used by other Plasmodium spp for 
binding iRBCs to host organs. This indicates that P. berghei may export proteins onto the surface of 
iRBCs to facilitate adherence to host tissues, e.g. the PfEMP1 protein expressed by Plasmodium 
falciparum. However, P. berghei does not contain any Pfemp1 orthologues, nor does it contain any 
protein with domains that bear homology to the domains of PfEMP1 [247]. The Plasmodium berghei 
proteins that are responsible for cytoadherence, and other proteins involved in the transportation of 
these adherence proteins to the iRBC membrane remain largely unknown.  
The existence of a correlation between the relative abundance of mutants in the blood and 
different tissues in 4 different strains of mice suggests that when Plasmodium berghei accumulates 
in the tissues, no mutants are lost in blood or vice versa.  However, mutants of ptex88 gene that was 
not grown in wild-type B6 mice but well grew in immune deficient rag1-/- mice mice (Table 3) is 
important for investigating host-parasite interaction further. Using our adoptive transfer protocol, we 
performed experiments to observe the effect of parasite proteins in the process of parasite clearance 
and growth. Initial analysis of the data for measuring parasite clearance (G0) and growth (G1+) 
suggested a role of PTEX88 (Plasmodium translocon of exportd protein 88) in the parasite 
clearance as more G0 parasite remained in the circulation following ATc treatment compared to 
vehicle-treated mice infected with the PbPTEX88-iKD parasite. Further analyses, using 
mathematical model, disclosed that although PTEX88 might have no role in the parasite 
clearance or infectivity, it caused delay in the maturation of parasite (34 hrs cycle for ATc treated 
compared vs. 24 h cycle for vehicle treated). A recent study has reported PTEX88 to facilitate entry 
of trafficking proteins, required for parasite development and survival, into the host cells. Moreover, 
it affects maturation in the early stage (ring stage) of the parasite life cycle compared to late 
stage. It has been shown that PTEX88 is involved in the sequestration and experimental cerebral 
malaria [223], and recently, Chisholm A et. al has found that PTEX88 interacts closely with 
HSP101 and discretely present in the parasitophorous vacuole membrane during ring stage of 
the parasite [245] [243]. Together, this experimental approach provided proof of concept that there 
may be genes that play a specific role for interacting with the host immune system. Future 
experiments required to follow larger numbers of genes, and begin the process of functionally testing 
candidates for immune-system dependent phenotypes, perhaps using competitive in vivo 
Clearance/Growth Assays in wild-type versus rag1-/- mice. 
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Chapter Six: 
Final discussion 
Malaria is a complex disease and its outcome depends on a wide variety of factors – including 
parasite species and strain, host immune responses, host and parasite metabolic pathways, and host 
and parasite genetic polymorphisms. Understanding the mechanisms by which host and parasite 
interact may be useful for developing novel therapeutic interventions in malaria [248, 249]. 
Therefore, this thesis has explored at organ-level, cellular-level and molecular level, various 
mechanisms by which infected hosts can control parasite growth in mouse models of blood-stage 
malaria. In addition, this thesis has also sought to define novel parasite factors, which enable the 
parasite to survive and grow within immune-competent hosts.   
Using an in vivo RBC adoptive transfer protocol developed in our laboratory, referred to as 
the “in vivo Clearance/Growth” assay, I have explored host and drug-mediated control during blood-
stage malaria. Although the prevailing view has been that host removal of pRBC is conducted by 
macrophages in the spleen and liver, in vivo evidence to support this is sparse. By following a single 
cohort of pRBC in the presence or absence of phagocytic cells, I revealed that these cells indeed play 
a partial role in removing pRBC from circulation. Furthermore, I showed that phagocytes in general, 
and the spleen in particular, are required to remove artesunate-affected parasites from circulation. 
Together, these data indicate that the mononuclear phagocytic system does function to remove pRBC, 
although its role in controlling parasite growth is rather modest. Previous reports showed that various 
host factors including the spleen and CD8+ T-cells are paradoxically required to support high parasite 
burdens during PbANKA infection [250].  Unpublished data from my group has since also shown 
that the net role of phagocytes in this model is actually to support parasite growth, despite my data 
proving their role in removing some pRBC. This data raises the concept that organs like the spleen 
and cells such as phagocytes may play multiple competing roles in parasite control.  For example, 
splenic phagocytes may serve to remove some pRBC, while simultaneously providing immune-
mediated signals such as systemic inflammatory cytokines that trigger endothelial activation and 
parasite sequestration. Further experimentation is warranted to examine the complex roles that 
phagocytes play in malaria.     
Next, I investigated in depth how anti-malarial drugs are so effective at controlling parasite 
numbers. Again, by following in detail a single cohort of pRBC, I showed that the anti-malarial drug 
artesunate prevented parasites from maturing in RBC.  As a result of this, parasites lingered in the 
first generation of RBC in circulation, rather than maturing and rupturing. Although, it might be the 
case that these parasites were in fact killed, in thesis it was not possible to determine this definitively.  
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Further experiments may require an adoptive transfer or other methods to determine the degree to 
which anti-malarial drugs kill parasites, as opposed to impairing or arresting their maturation. This 
work may be useful given that parasite dormancy under drug control is an important area of research 
[155, 182, 191, 192].   
Next, my data served to reveal a completely novel mechanism by which the host can control 
parasite growth, namely by directly slowing the maturation rate of parasites during acute infection.  
Prior to this work, the common view was that the duration of the blood-stage parasite life-cycle in 
vivo was fairly constant for a given species. Exposure of parasites in pRBC to an acute infection 
environment surprisingly slowed maturation, such that the life cycle was extended from 24 hours to 
40 hours. Moreover, this appeared to be a host response-dependent phenotype, since infected rag1-/- 
mice could not elicit impaired maturation. Thus, the phenomena suggests that the impaired maturation 
may be consequent to some host factors, rather than the parasite factors: however, in the acute 
inflammatory environment parasites may survive by escaping their clearance from the circulation. 
Future studies could aim to discover what aspects of the host response to infection might mediate this 
effect.  Moreover, it might be interesting to explore by transcriptomic studies, how the parasite senses 
and responses to the host environment.   
In a subsequent chapter of this thesis, I focused on a molecular aspect of host-mediated parasite 
control, via parasite-specific antibodies. Although the P. chabaudi and P. yoelii 17XNL mouse 
models have been established as examples of robust antibody-mediated immunity, in vivo 
mechanisms of action for these antibodies have not been studied. My data suggested that in both 
models, parasite-specific IgG antibodies protected not by binding to the surface of infected RBC and 
accelerating their clearance from circulation, but by targeting the free form of the parasite, merozoites. 
By binding to merozoites, this prevented parasites from transitioning from one generation of RBC to 
the next, which had dramatic effects on parasite numbers. Moreover, we could demonstrate that 
phagocytes played a partial role in antibody efficacy, while the complement components C3 and C5 
played no role in membrane attack complex (MAC)-mediated direct lysis of pRBCs. Previous in vitro 
studies have suggested that phagocytes are important for antibody-mediated parasite control either by 
opsonic phagocytosis or cellular inhibition [114, 251, 252] and my in vivo data is consistent with this. 
Recent data have suggested that C1q deposition [114] on the surface of antibody-coated merozoites 
might provide a mechanism by which antibodies function in human malaria. Future experiments are 
required to examine the role of C1q in antibody-mediated immunity in vivo.  
While the main emphasis of this thesis has been to explore host and drug-mediated 
mechanisms of parasite control, in my final Results chapter, I changed focus to examine parasite 
factors, namely genes that encode for exported proteins that might be required for blood-stage growth, 
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and specific interaction with immune-competent hosts. I chose to work in this area because a large 
proportion of Plasmodium genes remained uncharacterized. During blood-stage malaria parasites 
export hundreds of proteins into the host erythrocyte [253, 254]. Many of these genes have unknown 
functions, partly due to difficulties in manipulating the AT-rich Plasmodium genome by reverse 
genetic technology. Here, using knock-out PlasmoGEM vectors and high throughput, barcode-based 
NGS sequencing approaches [246] I identified a number of genes which were important for blood-
stage parasite growth. Importantly, I also revealed a number of genes that differentially in wild-type 
versus immune-deficient mice. For example, ptex88 knockout parasites within a pool of 107 other 
mutants survived very poorly in immune-competent mice yet grew well in rag1-/- mice that lack a 
robust pro-inflammatory response to infection. Further analysis of ptex88 knockdown parasites 
suggested a role for this gene in promoting parasite maturation rates in immune-replete mice.  Most 
importantly, my experimental approach provided proof of concept that there may be genes that are 
crucial for interacting with the host immune system but are functionally redundant in immune-
deficient environments. Future experiments should follow larger numbers of genes, and begin the 
process of functionally testing candidates for immune-system dependent phenotypes, perhaps using 
competitive in vivo Clearance/Growth Assays in wild-type versus rag1-/- mice.  
Concluding remarks 
By measuring parasite clearance and growth in vivo using the Clearance/Growth assay in 
mice, my thesis has explored the underlying mechanisms of host and drug-mediated control and 
parasite growth during blood-stage malaria in vivo. Most notably, acute responses in the host impaired 
parasite maturation rates and Plasmodium-specific antibodies prevented the transition from one RBC 
to the next. I also revealed that anti-malarial drugs generally do not accelerate pRBC clearance, but 
serve to impair or arrest maturation. Finally, a number of novel genes were discovered which are 
were essential for the blood-stage growth and interacting with the host immune system. Taken 
together, these data provide novel information on how malaria control might possibly be achieved in 
humans infected with Plasmodium species.  
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